Biofrontera (BFRI) S-1/A 13 Oct 23 IPO registration (amended) Financial data

Cover

Cover	6 Months Ended
	Jun. 30, 2023
Entity Addresses [Line Items]
Document Type	S-1/A
Amendment Flag	true
Amendment Description	Amendment No. 1
Entity Registrant Name	BIOFRONTERA INC.
Entity Central Index Key	0001858685
Entity Tax Identification Number	47-3765675
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	120 Presidential Way
Entity Address, Address Line Two	Suite 330
Entity Address, City or Town	Woburn
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01801
City Area Code	781
Local Phone Number	245-1325
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	Biofrontera Inc.
Entity Address, Address Line Two	120 Presidential Way
Entity Address, Address Line Three	Suite 330
Entity Address, City or Town	Woburn
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01801
City Area Code	781
Local Phone Number	245-1325
Contact Personnel Name	Prof. Dr. Hermann Luebbert

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 4,453	$ 17,208	$ 24,545
Investment, related party	5,900	10,500
Accounts receivable, net	2,193	3,748	3,784
Inventories, net	14,785	7,168	4,458
Prepaid expenses and other current assets	929	810	4,987
Total current assets	32,296	43,140	46,421
Property and equipment, net	175	204	267
Operating lease right-of-use assets	1,107	1,375
Intangible asset, net	2,823	3,032	3,450
Other assets	504	320	268
Total assets	36,905	50,884	53,219
Current liabilities:
Acquisition contract liabilities, net	7,121	6,942	3,242
Operating lease liabilities	489	498
Accrued expenses and other current liabilities	10,736	10,864	9,654
Line of credit	1,106
Total current liabilities	25,352	20,894	13,836
Long-term liabilities:
Acquisition contract liabilities, net	2,300	2,400	9,542
Warrant liabilities	1,440	2,843	12,854
Operating lease liabilities, non-current	600	848
Other liabilities	40	21	5,649
Total liabilities	29,732	27,006	41,881
Commitments and contingencies (Note 18)
Stockholders’ equity:
Preferred Stock, $0.001 par value, 20,000,000 shares authorized, zero shares issued and outstanding as of June 30, 2023 and December 31, 2022
Common Stock, $0.001 par value, 15,000,000 shares authorized; 1,367,628 and 1,359,040 shares issued and outstanding as of June 30, 2023 and December 31, 2022		1	1
Additional paid-in capital		103,396	90,216
Accumulated deficit	(96,834)	(79,519)	(78,879)
Total stockholders’ equity	7,173	23,878	11,338
Total liabilities and stockholders’ equity	36,905	50,884	53,219
Revision of Prior Period, Adjustment [Member]
Stockholders’ equity:
Common Stock, $0.001 par value, 15,000,000 shares authorized; 1,367,628 and 1,359,040 shares issued and outstanding as of June 30, 2023 and December 31, 2022	27	27
Additional paid-in capital	103,980	103,370
Total stockholders’ equity		23,878	11,338
Related Party [Member]
Current assets:
Investment, related party	5,935	10,548
Other receivables, related party	4,001	3,658	8,647
Other receivables long term, related party		2,813	2,813
Current liabilities:
Accounts payable, related parties	4,657	1,312	282
Nonrelated Party [Member]
Current liabilities:
Accounts payable, related parties	$ 1,243	$ 1,278	$ 658

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	20,000,000	20,000,000	20,000,000
Preferred Stock, Shares Issued	0	0	0
Preferred Stock, Shares Outstanding	0	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001	$ 0.001
Common Stock, Shares Authorized	15,000,000	15,000,000	15,000,000
Common Stock, Shares, Issued	1,367,628	1,334,950	855,237
Common Stock, Shares, Outstanding	1,367,628	1,334,950	855,237
Revision of Prior Period, Adjustment [Member]
Common Stock, Shares, Issued		1,359,040
Common Stock, Shares, Outstanding		1,359,040

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Product revenues, net	$ 5,830	$ 4,441	$ 14,544	$ 14,177	$ 28,541	$ 24,043
Revenues, related party	18	16	36	31	133	57
Total revenues, net	5,848	4,457	14,580	14,208	28,674	24,100
Operating expenses
Research and development	11		11		733	697
Restructuring costs						752
Change in fair value of contingent consideration	100	(1,900)	(100)	(1,900)	(3,800)	(1,402)
Total operating expenses	14,547	10,669	28,770	23,530	47,255	49,301
Loss from operations	(8,699)	(6,212)	(14,190)	(9,322)	(18,581)	(25,201)
Other income (expense)
Change in fair value of warrants	375	5,371	1,403	14,082	19,017	(12,801)
Warrant inducement expense					(2,629)
Change in fair value of investment, related party	(1,482)		(4,424)		1,747
Interest expense, net	(79)	(38)	(114)	(71)	(195)	(344)
Other income, net	62	29	30	52	33	689
Total other income (expense)	(1,124)	5,362	(3,105)	14,063	17,973	(12,456)
Income (loss) before income taxes	(9,823)	(850)	(17,295)	4,741	(608)	(37,657)
Income tax expense	14		20	30	32	56
Net income (loss)	$ (9,837)	$ (850)	$ (17,315)	$ 4,711	$ (640)	$ (37,713)
Income (loss) per common share:
Basic	$ (7.23)	$ (0.90)	$ (12.73)	$ 5.24	$ (0.61)	$ (85.63)
Diluted	$ (7.23)	$ (0.90)	$ (12.73)	$ 5.22	$ (0.61)	$ (85.63)
Weighted-average common shares outstanding:
Basic	1,360,739	941,175	1,359,894	898,444	1,056,988	440,412
Diluted	1,360,739	941,175	1,359,894	902,209	1,056,988	440,412
Related Party [Member]
Operating expenses
Cost of revenues	$ 2,772	$ 2,402	$ 7,319	$ 7,377	$ 14,618	$ 12,222
Selling, general and administrative	92	346	119	441	733	697
Nonrelated Party [Member]
Operating expenses
Cost of revenues	116	152	167	327	567	520
Selling, general and administrative	$ 11,456	$ 9,669	$ 21,254	$ 17,285	$ 35,137	$ 36,512

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Common Stock [Member] Revision of Prior Period, Adjustment [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Revision of Prior Period, Adjustment [Member]	Retained Earnings [Member]	Retained Earnings [Member] Revision of Prior Period, Adjustment [Member]	Total	Revision of Prior Period, Adjustment [Member]
Beginning balance, value at Dec. 31, 2020	$ 0		$ 46,993		$ (41,166)		$ 5,828
Beginning balance, shares at Dec. 31, 2020	400,000
Issuance of common stock in exchange for investment, related party	$ 0		14,943				14,943
Issuance of common stock in exchange for investments in equity securities, shares	180,000
Issuance of common stock and warrants under private placement, net of negligible issuance costs	$ 0		2,690				2,690
Issuance of common stock and warrants under private placement, net of issuance costs, shares	67,500
Exercise of common stock warrants	$ 0		13,238				$ 13,238
Exercise of common stock warrants, shares	132,380
Exercise of pre-funded warrants	$ 0		12,223				$ 12,223
Exercise of pre-funded warrants, shares	75,357
Stock based compensation			129				129
Net income (loss)					(37,713)		(37,713)
Ending balance, value at Dec. 31, 2021	$ 17	$ 1	90,200	$ 90,216	(78,879)	$ (78,879)	11,338	$ 11,338
Ending balance, shares at Dec. 31, 2021	855,238	855,237
Stock based compensation			1,068				1,068
Net income (loss)					4,711		4,711
Issuance of shares for vested restricted stock units
Issuance of shares for vested restricted stock units, shares	2,835
Issuance of common stock and warrants under private placement, net of issuance costs	$ 2		114				116
Issuance of common stock and warrants under private placement, net of issuance costs, shares	92,500
Ending balance, value at Jun. 30, 2022	$ 19		91,382		(74,168)		17,233
Ending balance, shares at Jun. 30, 2022	950,573
Beginning balance, value at Dec. 31, 2021	$ 17	$ 1	90,200	90,216	(78,879)	(78,879)	$ 11,338	11,338
Beginning balance, shares at Dec. 31, 2021	855,238	855,237
Issuance of common stock in exchange for investment, related party		$ 0		3,683				3,683
Issuance of common stock in exchange for investments in equity securities, shares		157,402
Issuance of common stock and warrants under private placement, net of negligible issuance costs		$ 0		117				117
Issuance of common stock and warrants under private placement, net of issuance costs, shares		92,500
Exercise of common stock warrants, shares
Exercise of pre-funded warrants		$ 0		2,842				2,842
Exercise of pre-funded warrants, shares		78,450
Stock based compensation				1,852				1,852
Net income (loss)						(640)	$ (640)	(640)
Exercise of PIPE warrants		$ 0		4,686				4,686
Exercise of PIPE warrants, shares		142,857
Issuance of shares for vested restricted stock units
Issuance of shares for vested restricted stock units, shares		8,504
Ending balance, value at Dec. 31, 2022	$ 27	$ 1	103,370	103,396	(79,519)	(79,519)	23,878	23,878
Ending balance, shares at Dec. 31, 2022	1,359,040	1,334,950
Beginning balance, value at Mar. 31, 2022	$ 17		90,717		(73,318)		17,416
Beginning balance, shares at Mar. 31, 2022	855,238
Stock based compensation			551				551
Net income (loss)					(850)		(850)
Issuance of shares for vested restricted stock units
Issuance of shares for vested restricted stock units, shares	2,835
Issuance of common stock and warrants under private placement, net of issuance costs	$ 2		114				116
Issuance of common stock and warrants under private placement, net of issuance costs, shares	92,500
Ending balance, value at Jun. 30, 2022	$ 19		91,382		(74,168)		17,233
Ending balance, shares at Jun. 30, 2022	950,573
Beginning balance, value at Dec. 31, 2022	$ 27	$ 1	103,370	$ 103,396	(79,519)	$ (79,519)	$ 23,878	$ 23,878
Beginning balance, shares at Dec. 31, 2022	1,359,040	1,334,950
Exercise of common stock warrants, shares
Stock based compensation			610				$ 610
Net income (loss)					(17,315)		(17,315)
Issuance of shares for vested restricted stock units
Issuance of shares for vested restricted stock units, shares	8,588
Ending balance, value at Jun. 30, 2023	$ 27		103,980		(96,834)		7,173
Ending balance, shares at Jun. 30, 2023	1,367,628
Beginning balance, value at Mar. 31, 2023	$ 27		103,721		(86,997)		16,751
Beginning balance, shares at Mar. 31, 2023	1,359,040
Stock based compensation			259				259
Net income (loss)					(9,837)		(9,837)
Issuance of shares for vested restricted stock units
Issuance of shares for vested restricted stock units, shares	8,588
Ending balance, value at Jun. 30, 2023	$ 27		$ 103,980		$ (96,834)		$ 7,173
Ending balance, shares at Jun. 30, 2023	1,367,628

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($) $ in Millions		12 Months Ended
	Dec. 31, 2021	Dec. 31, 2021
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Payments of Stock Issuance Costs	$ 3.1	$ 3.1
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Payments of Stock Issuance Costs		$ 0.3

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net income (loss)	$ (17,315)	$ 4,711	$ (640)	$ (37,713)
Adjustments to reconcile net income (loss) to cash flows used in operations
Depreciation	44	54	101	122
Amortization of right-of-use assets	265		653
Amortization of acquired intangible assets	209	209	418	418
Change in fair value of investment, related party	4,424		(1,747)
Change in fair value of contingent consideration	(100)	(1,900)	(3,800)	(1,402)
Change in fair value of warrant liabilities	(1,403)	(14,082)	(19,017)	12,801
Warrant inducement expense			2,629
Stock-based compensation	610	1,068	1,852	129
Provision for inventory obsolescence		100	100	33
Provision for doubtful accounts	64	133	106	44
Non-cash interest expense	190	179	358	358
Changes in operating assets and liabilities:
Accounts receivable	1,491	1,650	(70)	(612)
Other receivables, related party	2,397	5,602	4,990	(11,387)
Prepaid expenses and other assets	(302)	3,698	4,154	(3,809)
Inventories	(7,617)	(4,449)	(2,810)	2,592
Accounts payable and related party payables	3,380	1,280	912	(773)
Operating lease liabilities	(255)		(781)
Accrued expenses and other liabilities	(107)	(240)	(3,607)	12,484
Cash flows used in operating activities	(14,025)	(1,987)	(16,199)	(26,715)
Cash flows from investing activities
Sales of equity investment, related party	178
Purchases of investment, related party			(5,118)
Purchases of property and equipment	(14)	(36)	(38)	(11)
Cash flows provided by (used) in investing activities	164	(36)	(5,156)	(11)
Cash flows from financing activities
Proceeds from issuance of common stock and warrants upon initial public offering, net of issuance costs				14,943
Proceeds from line of credit	5,700
Proceeds from issuance of common stock and warrants in private placement, net of issuance costs		9,391	9,391	14,995
Proceeds from exercise of warrants			4,630	13,253
Repayment of line of credit	(4,594)
Cash flows provided by financing activities	1,106	9,391	14,021	43,191
Net increase (decrease) in cash and cash equivalents	(12,755)	7,368	(7,334)	16,465
Cash, cash equivalents and restricted cash, at the beginning of the period	17,408	24,742	24,742	8,277
Cash, cash equivalents and restricted cash, at the end of the period	4,653	32,110	17,408	24,742
Supplemental disclosure of cash flow information
Interest paid		4	1	2
Income taxes paid, net		$ 30	32	56
Supplemental non-cash investing and financing activities
Conversion of warrant liability to equity in connection with exercise of warrants			6,840	12,208
Issuance of common shares in exchange for investment, related party			3,683
Addition of right-of-use assets in exchange for operating lease liabilities			234
Issuance costs included in accrued expenses and other liabilities				44
Non-cash purchase of fixed assets				$ 8

Business Overview

Business Overview	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview	1. Business Overview Biofrontera Inc (the “Company” or “Biofrontera”) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (“PDT”) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions as well as impetigo, a bacterial skin infection. ® Biofrontera Inc. includes its wholly owned subsidiary Bio-FRI GmbH (“Bio-FRI”), a limited liability company organized under the laws of Germany. Our subsidiary, Bio-FRI was formed on February 9, 2022, as a German presence to facilitate our relationship with the Ameluz Licensor. Our principal licensed product is Ameluz ® ® ® ® Our second prescription drug licensed product is Xepi® (ozenoxacin cream, 1%), a topical non-fluorinated quinolone that inhibits bacterial growth. Currently, no antibiotic resistance against Xepi® is known and it has been specifically approved by the FDA for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or Streptococcus pyogenes. It is approved for use in the United States in adults and children 2 months and older. We are currently selling Xepi® for this indication in the United States under an exclusive license and supply agreement, as amended (“Xepi LSA”) with Ferrer Internacional S.A. (“Ferrer”) that was assumed by Biofrontera on March 25, 2019 through our acquisition of Cutanea Life Sciences, Inc.(“Cutanea”). There has been limited revenue during the current reporting periods and recent developments with the third-party manufacturer that was providing our supply of Xepi® have resulted in further delays of our commercialization of the product. However, Ferrer is qualifying a new Contract manufacturer, Cambrex, which is expected to begin production early in 2024. Once the new third-party manufacturer is qualified, we expect the supply of Xepi® will meet future needs. Liquidity and Going Concern The Company’s primary sources of liquidity are its existing cash balances, cash collected from the sales of its products, proceeds from the sale of our investment, related party, and cash flows from a revolving line of credit. As of June 30, 2023, we had cash and cash equivalents of $ 4.5 million and investment, related party of $ 5.9 million, compared to $ 17.2 million and $ 10.5 million as of December 31, 2022, respectively. Since we commenced operations in 2015, we have generated significant losses. For the six months ended June 30, 2023 and 2022, we incurred loss from operations of $ 14.2 million and $ 9.3 million, respectively. We incurred net cash outflows from operations of $ 14.0 million and $ 2.0 million, for the same periods, respectively. We had an accumulated deficit as of June 30, 2023 of $ 96.8 million. The Company’s short-term material cash requirements include working capital needs and satisfaction of contractual commitments (see Note 18. Commitments and Contingencies 7.3 million (see Note 3. Acquisition Contract Liabilities 2.4 million. Additionally, we expect to continue to incur operating losses due to significant discretionary sales and marketing, medical affairs, and dermatology community outreach efforts as we seek to expand the commercialization of our licensed products in the United States. We also expect to incur additional expenses to add and improve operational, financial and information systems and personnel, including personnel to support our product commercialization efforts. In addition, we expect to incur costs to continue to comply with corporate governance, regulatory reporting and other requirements applicable to us as a public company in the U.S. In connection with our assessment of going concern considerations under applicable accounting standards, the Company’s management has determined that, based on our growth plans, upcoming inventory purchases, and a final settlement payment, substantial doubt exists about our ability to continue as a going concern for at least one year from the date the unaudited condensed financial statements were issued. The future viability of the Company is dependent on its ability to continue to execute its growth plan and raise additional capital or find alternative methods of financing to fund its operations until cash flow from operations is sufficient. Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern. No assurance can be given that the Company will be successful in these efforts. Accordingly, management has concluded that substantial doubt exists about the company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these financial statements. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.	1. Organization and Business Overview Business Overview Biofrontera Inc., a Delaware Corporation, (the “Company” or “ Biofrontera”) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (“PDT”) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions as well as impetigo, a bacterial skin infection. Our principal licensed product is Ameluz ® ® ® ® Our second prescription drug licensed product is Xepi® (ozenoxacin cream, 1%), a topical non-fluorinated quinolone that inhibits bacterial growth. Currently, no antibiotic resistance against Xepi® is known and it has been specifically approved by the FDA for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or Streptococcus pyogenes. It is approved for use in the United States in adults and children 2 months and older. We are currently selling Xepi® for this indication in the United States under an exclusive license and supply agreement, as amended (“Xepi LSA”) with Ferrer Internacional S.A. (“Ferrer”) that was assumed by Biofrontera on March 25, 2019 through our acquisition of Cutanea Life Sciences, Inc.(“Cutanea”). There has been limited revenue during the current reporting periods and recent developments with the third-party manufacturer that was providing our supply of Xepi® have resulted in further delays of our commercialization of the product. However, Ferrer is qualifying a new Contract manufacturer, Cambrex, which is expected to begin production early in 2024. Once the new third-party manufacturer is qualified, we expect the supply of Xepi® will meet our future market demand. Biofrontera Inc. includes its wholly owned subsidiary Bio-FRI GmbH (“Bio-FRI”), a limited liability company organized under the laws of Germany. Our subsidiary, Bio-FRI was formed on February 9, 2022, as a German presence to facilitate our relationship with the Ameluz Licensor. Liquidity and Going Concern The Company’s primary sources of liquidity are its existing cash balances, cash collected from the sales of its products, and cash flows from financing transactions. During the year ended December 31, 2022, we received proceeds of $ 9.4 million from the issuance of common stock and warrants in a private placement, net of issuance costs, and $ 4.6 million from the exercise of common stock warrants (See Note 19. Stockholders’ Equity 17.2 million, compared to $ 24.5 million as of December 31, 2021. Our unaudited estimated ending cash balance at September 30, 2023 was $ 3.1 million. Since we commenced operations in 2015, we have generated significant losses and have incurred net cash outflows from operations of $ 16.2 million and $ 26.7 million for the years ended December 31, 2022 and 2021. The Company had an accumulated deficit as of December 31, 2022 of $ 79.5 million. The Company’s short-term material cash requirements include working capital needs and satisfaction of contractual commitments, Maruho start-up payments of $ 7.3 million (see Note 3. Acquisition Contract Liabilities Note 24, Commitments and Contingencies Additionally, we expect to continue to incur operating losses due to significant discretionary sales and marketing, medical affairs, and dermatology community outreach efforts as we seek to expand the commercialization of our licensed products in the United States. We also expect to incur additional expenses to add and improve operational, financial and information systems and personnel, including personnel to support our product commercialization efforts. In addition, we expect to incur costs to continue to comply with corporate governance, regulatory reporting and other requirements applicable to us as a public company in the United States. In connection with our assessment of going concern considerations under applicable accounting standards, the Company’s management has determined that substantial doubt exists about our ability to continue as a going concern for at least one year from the date these financial statements were issued. The future viability of the Company is dependent on management’s plans to continue to execute its growth plan and raise additional capital or find alternative methods of financing to fund its operations until cash flow from operations is sufficient. Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern. No assurance can be given that the Company will be successful in these efforts. Accordingly, management has concluded that substantial doubt exists about the company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these financial statements. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. There could be a material adverse effect on the Company and its financial statements if management’s plans are not achieved on a timely basis.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis for Preparation of the Financial Statements The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the Company’s opinion, the unaudited condensed consolidated financial statements include all material adjustments, all of which are of a normal and recurring nature, necessary to present fairly the Company’s financial position as of June 30, 2023, the Company’s operating results for the three and six months ended June 30, 2023 and 2022, and the Company’s cash flows for the six months ended June 30, 2023 and 2022. The accompanying financial information as of December 31, 2022 is derived from audited financial statements. Interim results are not necessarily indicative of results for a full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 13, 2023. All amounts shown in these financial statements and tables are in thousands and amounts in the notes are in millions, except percentages and per share and share amounts. The Company’s significant accounting policies are discussed in Note 2—Summary of Significant Accounting Policies Research and Development Costs Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct research and development activities, and other operational costs related to the Company’s research and development activities. Reverse Stock Split On July 3, 2023 Biofrontera Inc. effected a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $ 0.001 par value (the “Common Stock”). The Common Stock began trading on the Nasdaq Capital Market on a post-split basis on July 5, 2023. All information included in these consolidated financial statements has been adjusted, on a retrospective basis, to reflect the Reverse Stock Split as if it had been effective from the beginning of the earliest period presented, unless otherwise stated. All outstanding securities entitling their holders to purchase shares of Common Stock or acquire shares of Common Stock, including stock options, restricted stock units, and warrants, were adjusted as a result of the Reverse Stock Split, as required by the terms of those securities. Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions by management that affect the reported amounts of assets and liabilities, as well as disclosure of contingent assets and liabilities, as reported on the balance sheet date, and the reported amounts of revenues and expenses arising during the reporting period. The main areas in which assumptions, estimates and the exercising of judgment are appropriate relate to, valuation allowances for receivables and inventory, valuation of contingent consideration and warrant liabilities, realization of intangible and other long-lived assets, product sales allowances and reserves, share-based payments and income taxes including deferred tax assets and liabilities. Estimates are based on historical experience and other assumptions that are considered appropriate in the circumstances. They are continuously reviewed but may vary from the actual values. Recently Adopted Accounting Pronouncements In September 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments	2. Summary of Significant Accounting Policies Basis for Preparation of the Consolidated Financial Statements The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). These consolidated financial statements include the accounts of our wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The information presented reflects the application of significant accounting policies described below. All amounts shown in these financial statements and tables are in thousands and amounts in the notes are in millions, except percentages and per share and share amounts. Segment Reporting Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s operating results. We operate in a single reporting segment, the commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases within the U.S. All business operations focus on the products Ameluz ® ® ® Reverse Stock Split On July 3, 2023 Biofrontera Inc. effected a 1-for-20 0.001 All information included in these consolidated financial statements has been adjusted, on a retrospective basis, to reflect the Reverse Stock Split as if it had been effective from the beginning of the earliest period presented, unless otherwise stated. All outstanding securities entitling their holders to purchase shares of Common Stock or acquire shares of Common Stock, including stock options, restricted stock units, and warrants, were adjusted as a result of the Reverse Stock Split, as required by the terms of those securities. Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions by management that affect the reported amounts of assets and liabilities, as well as disclosure of contingent assets and liabilities, as reported on the balance sheet date, and the reported amounts of revenues and expenses arising during the reporting period. The main areas in which assumptions, estimates and the exercising of judgment are appropriate relate to valuation allowances for receivables and inventory, valuation of contingent consideration and warrant liabilities, realization of intangible and other long-lived assets, product sales allowances and reserves, share-based payments and income taxes including deferred tax assets and liabilities. Estimates are based on historical experience and other assumptions that are considered appropriate in the circumstances. They are continuously reviewed but may vary from the actual values. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents. The Company maintains its cash balances at financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”). The FDIC provides coverage of up to $ 250,000 per depositor, per financial institution. At December 31, 2022, approximately $ 16.8 million of the Company’s cash balances were in excess of FDIC limits. The Company has not experienced any losses on these accounts and management does not believe that the Company is exposed to any significant risks. Restricted Cash Restricted cash consists primarily of deposits of cash collateral held in accordance with the terms of our corporate credit cards, in addition to one deposit held for a sublease (see Note 13. Statement of Cash Flows Reconciliation) Investment, Related Party The Company accounts for its investment, related party in accordance with ASC 321, Investments — Equity Securities Accounts Receivable Accounts receivables are reported at their net realizable value. Any value adjustments are booked directly against the relevant receivable. We have standard payment terms that generally require payment within approximately 30 to 90 days. Management performs ongoing credit evaluations of its customers. An allowance for potentially uncollectible accounts is provided based on history, economic conditions, and composition of the accounts receivable aging. In some cases, the Company makes allowances for specific customers based on these and other factors. Provisions for the allowance for doubtful accounts are recorded in selling, general and administrative expenses in the accompanying statements of operations. Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, accounts receivable and other receivables, related party. The Company maintains all of its cash and cash equivalents at a single accredited financial institution, in amounts that exceed federally insured limits. The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers using our products. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. Other receivables, related party consists of a receivable due from Biofrontera AG for its 50% share of a legal settlement and related costs for which they are jointly and severally liable for the total settlement amount. The Company has a contractual right to repayment of its share of the settlement payment from Biofrontera AG under the Settlement Allocation Agreement entered into on December 9, 2021, which provided that the settlement payments would first be made by the Company and then reimbursed by Biofrontera AG for its share. Although this receivable has credit risk, it is mitigated by the Settlement Allocation Agreement as amended on March 31, 2022, which provides certain remedies to the Company, if Biofrontera AG fails to make timely reimbursements, which the Company may implement in its sole discretion, including the ability to charge interest at a rate of 6.0% per annum for each day that any reimbursement is past due and the ability to offset any overdue reimbursement amounts against payments owed to Biofrontera AG by the Company (including amounts owed under the Company’s license and supply agreement for Ameluz ® We are dependent on two suppliers, Biofrontera Pharma GmbH and Ferrer Internacional S.A., to supply drug products, including all underlying components, for our commercial efforts. These efforts could be adversely affected by a significant interruption in the supply of our finished products. Inventories Finished goods consist of pharmaceutical products purchased for resale and are stated at the lower of cost or net realizable value. Cost is calculated by applying the first-in-first-out method (FIFO). Inventory costs include the purchase price of finished goods and freight-in costs. The Company regularly reviews inventory quantities on hand and writes down to its net realizable value any inventory that it believes to be impaired. Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. Once inventory is written down and a new cost basis is established, it is not written back up if demand increases. Property and Equipment Property and equipment are recorded at cost less accumulated depreciation. Depreciation is generally applied straight-line over the estimated useful life of assets. Leasehold improvements are amortized over the shorter of the asset’s estimated useful life or the lease term. The estimated useful lives of property and equipment are: Schedule of Estimated Useful Lives of Property, Plant and Equipment Estimated Useful Life in Years Computer equipment 3 Computer software 3 Furniture and fixtures 3 5 Leasehold improvements Shorter of estimated useful lives or the term of the lease Machinery & equipment 3 4 The cost and accumulated depreciation of assets retired or sold are removed from the respective asset category, and any gain or loss is recognized in our statements of operations. Intangible Assets Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized. Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases (Topic 842), to enhance the transparency and comparability of financial reporting related to leasing arrangements. The Company adopted the standard effective January 1, 2022. Using the optional transition method, prior period financial statements have not been recast to reflect the new lease standard. The adoption of the new lease standard resulted in the addition of an operating lease right-of-use asset and an operating lease liability in the amount of $ 1.8 million to the consolidated balance sheet as of January 1, 2022. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate (“IBR”), which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Given the absence of an outstanding debt agreement, a synthetic credit rating analysis was used in estimating the Company’s IBR. Based on a synthetic credit rating of Ba3 and a term of 3.33 to six years, the IBR was determined to be 6% for lease liabilities at inception and 8.5% for 2022 lease liabilities . No adjustments to the right-of-use asset were required for items such as initial direct costs paid or incentives received. The Company has elected to adopt the practical expedient provided in ASC 842 and not reassess leases that existed prior to the commencement date, 1). Whether any expired or existing contracts are or contain leases, 2). Lease classification, or 3). Initial indirect costs for any existing leases. The Company has elected to combine lease and non-lease components as a single component for certain asset classes, when applicable. Operating leases are recognized on the balance sheet as operating lease right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. Impairment of Long-Lived Assets The Company considers whether events or changes in facts and circumstances, both internally and externally, may indicate that an impairment of long-lived assets held for use, including right-of-use assets, are present. To the extent indicators or impairment exist, the determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset, the assets are written down to their estimated fair values and the loss is recognized in the statements of operations. Refer to Note 12. Intangible Asset, Net. Contingent Consideration Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. For contingent consideration, management is responsible for determining the appropriate valuation model and estimated fair value, and in doing so, considers a number of factors, including information provided by an outside valuation advisor. Contingent consideration liabilities are reported at their estimated fair values based on probability-adjusted present values of the consideration expected to be paid, using significant inputs and estimates. Key assumptions used in these estimates include probability assessments with respect to the likelihood of achieving certain milestones and discount rates consistent with the level of risk of achievement. The fair value of contingent consideration liabilities are remeasured each reporting period, with changes in the fair value included in current operations. The remeasured liability amount could be significantly different from the amount at the acquisition date, resulting in material charges or credits in future reporting periods. Contingencies Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable, and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management’s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure. Significant judgment is required in both the determination of probability and as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. Legal costs associated with legal proceedings are expensed when incurred. Derivative Instruments The Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in FASB Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and Derivatives and Hedging (“ASC 815”). Warrants classified as equity are recorded at fair value as of the date of issuance on the Company’s consolidated balance sheets and no further adjustments to their valuation are made. Warrants classified as derivative liabilities that require separate accounting as liabilities are recorded on the Company’s consolidated balance sheets at their fair value on the date of issuance and are revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using the Black-Scholes-Merton (“BSM”) model and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for future financings, expected volatility, expected life, yield, and risk-free interest rate. At their issuance date in October 2021, the IPO Warrants (see Note 19. Stockholders’ Equity) were accounted for as equity as these instruments met all of the requirements for equity classification under ASC 815-40. The Purchase Warrants issued in connection with the private placement offerings completed on December 1 , Note 4. Fair Value Measurements. Fair Value Measurements The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC 820, Fair Value Measurements and Disclosures Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 – Unobservable inputs using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Fair Value of Financial Instruments The carrying amounts reflected in the consolidated balance sheets for cash and cash equivalents, accounts receivable, other receivables, accounts payable and start-up cost financing included in acquisition contract liabilities approximate their fair values, due to their short-term nature. Revenue Recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers To determine revenue recognition, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when collectability of the consideration to which we are entitled in exchange for the goods or services we transfer to the customer is determined to be probable. The Company realizes its revenue primarily through the sales of its Ameluz ® Xepi ® The payment terms for sales of our pharmaceutical products are generally short-term payment terms with the possibility of volume-based discounts, co-pay assistance discounts, or other rebates. BF RhodoLED ® Variable Consideration Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which sales reserves are established and which result from discounts, rebates and other incentives that are offered within contracts between the Company and its customers. Components of variable consideration include trade discounts and allowances, product returns, government rebates, and other incentives such as patient co-pay assistance. Variable consideration is recorded on the balance sheet as either a reduction of accounts receivable, if expected to be claimed by a customer, or as a current liability, if expected to be payable to a third party other than a customer. Where appropriate, these estimates take into consideration relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. These reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, and record any necessary adjustments in the period such variances become known. Trade Discounts and Allowances Government and Payor Rebates Other Incentives ® Royalties For arrangements that include sales-based royalties, the Company recognizes royalty expense at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Royalty expense is recognized as cost of revenues. Product Warranty The Company generally provides a 36-month warranty for sales of BF-RhodoLED ® ® Contract Costs Incremental costs of obtaining a contract with a customer may be recorded as an asset if the costs are expected to be recovered. As a practical expedient, we recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. Sales commissions earned by the Company’s sales force are considered incremental costs of obtaining a contract. To date, we have expensed sales commissions as these costs are generally attributed to periods shorter than one year. Sales commissions are included in selling, general and administrative expenses. Cost of Revenues Cost of revenues is comprised of purchase costs of our products, third party logistics and distribution costs including packaging, freight, transportation, shipping and handling costs, and inventory adjustment due to expiring products, as well as sales-based royalties. Logistics and distribution costs totaled $ 0.5 million and $ 0.4 million for the years ended December 31, 2022 and 2021, respectively. Share-Based Compensation The Company measures and recognizes share-based compensation expense for equity awards based on fair value at the grant date. The Company uses the Black-Scholes-Merton (“BSM”) option pricing model to calculate fair value of its stock option grants. The compensation cost for restricted stock awards is based on the closing price of the Company’s common stock on the date of grant. Share-based compensation expense recognized in the statements of operations is based on the period the services are performed and recognized as compensation expense on a straight-line basis over the requisite service period. The Company accounts for forfeitures as they occur. The BSM option pricing model requires the input of subjective assumptions, including the risk-free interest rate, the expected volatility of the value of the Company’s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management’s judgment. If factors change and different assumptions are used, the share-based compensation expense could be materially different in the future. These assumptions are estimated as follows: Risk-Free Interest Rate. The risk-free rate is based on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term. Expected Volatility. The Company based the volatility assumption on a weighted average of the peer group re-levered equity volatility with 80 % weight and the warrant implied volatility with 20 % weight. The peer group was developed based on companies in the biotechnology industry whose shares are publicly traded. Due to our limited historical data and the long-term nature of the awards, the peer group volatility was more heavily weighted. Expected Term. The expected term represents the period of time that options are expected to be outstanding. Due to the lack of historical exercise data and given the plain vanilla nature of the options granted by the Company, the expected term is determined using the “simplified” method, as prescribed in SEC Staff Accounting Bulletin (“SAB”) No. 107 (“SAB 107”), whereby the expected life equals the average of the vesting term and the original contractual term. Dividend Yield. The dividend yield is 0 % as the Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, a dividend on its common stock. Foreign Currency Transactions Transactions realized in currencies other than USD are reported using the exchange rate on the date of the transaction. Selling, General and Administrative Expense Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with our sales force, commercial support personnel, personnel in executive and other administrative functions, as well as medical affairs professionals. Other selling, general and administrative expenses include marketing, advertising, and other commercial costs to support the commercial operation of our product and professional fees for legal, consulting, and other general and administrative costs. Advertising costs are expensed as incurred. For the years ended December 31, 2022 and 2021, advertising costs totaled $ 0.1 million and $ 0.5 million, respectively. Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, Income Taxes The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. Net Loss per Share Basic and diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. When the effects are not anti-dilutive, diluted earnings per share is computed by dividing the Company’s net income attributable to common stockholders by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares outstanding during the period, including stock options, restricted stock units, and warrants, using the treasury stock method. Recently Issued Accounting Pronouncements In September 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

Acquisition Contract Liabilitie

Acquisition Contract Liabilities	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisition Contract Liabilities	3. Acquisition Contract Liabilities On March 25, 2019, we entered into an agreement (as amended, the “Share Purchase Agreement”) with Maruho Co, Ltd. (“Maruho”) to acquire 100 % of the shares of Cutanea Life Sciences, Inc. (“Cutanea”). As of the date of the acquisition, Maruho Co, Ltd. owned approximately 29.9 % of Biofrontera AG through its fully owned subsidiary Maruho Deutschland GmbH. Biofrontera AG is our former parent, and currently a significant shareholder. Pursuant to the Share Purchase Agreement, Maruho agreed to provide $ 7.3 million in start-up cost financing for Cutanea’s redesigned business activities (“start-up costs”). These start-up costs are to be paid back to Maruho by the end of 2023 in accordance with contractual obligations related to an earn-out arrangement. In addition, as part of the earn-out arrangement with Maruho, the product profit amount from the sale of Cutanea products as defined in the share purchase agreement will be shared equally between Maruho and Biofrontera until 2030 (“contingent consideration”). In connection with this acquisition in 2019, we recorded the $ 7.3 million in start-up cost financing, a $ 1.7 million contract asset related to the benefit associated with the non-interest-bearing start-up cost financing and $ 6.5 million of contingent consideration related to the estimated profits from the sale of Cutanea products to be shared equally with Maruho (see Note 18. Commitment and contingencies – Cutanea payments) The contract asset related to the start-up cost financing is amortized on a straight-line basis using a 6.0 % interest rate over the 57 -month term of the financing arrangement, which ends on December 31, 2023 . The contract asset is shown net of the related start-up cost financing within acquisition contract liabilities, net. The contingent consideration was recorded at acquisition-date fair value using a Monte Carlo simulation with an assumed discount rate of approximately 6.0 % over the applicable term. The contingent consideration is recorded within acquisition contract liabilities, net. The amount of contingent consideration that could be payable is not subject to a cap under the agreement. The contingent consideration that could be payable was valued at $ 2.3 million with payments coming due May of 2028 through May 2030. The Company re-measures contingent consideration and re-assesses the underlying assumptions and estimates at each reporting period utilizing a scenario-based method. Acquisition contract liabilities, net consist of the following: Schedule of Acquisition Contract Liabilities (in thousands)  June 30, 2023 December 31, 2022 Short-term acquisition contract liabilities: Contingent consideration $ 2,300 $ 2,400 Start-up cost financing 7,300 7,300 Contract asset (179 ) (358 ) Acquisition contract liabilities, net $ 7,121 $ 6,942 Long-term acquisition contract liabilities: Contingent consideration $ 2,300 $ 2,400 Total acquisition contract liabilities: Contingent consideration $ 2,300 $ 2,400 Start-up cost financing 7,300 7,300 Contract asset (179 ) (358 ) Total acquisition contract liabilities, net $ 9,421 $ 9,342	3. Acquisition Contract Liabilities On March 25, 2019, we entered into an agreement (as amended, the “Share Purchase Agreement”) with Maruho Co, Ltd. (“Maruho”) to acquire 100 % of the shares of Cutanea Life Sciences, Inc. (“Cutanea”). As of the date of the acquisition, Maruho Co, Ltd. Owned approximately 29.9 % of Biofrontera AG through its fully owned subsidiary Maruho Deutschland GmbH. Biofrontera AG is our former parent, and currently a significant shareholder. Pursuant to the Share Purchase Agreement, Maruho agreed to provide $ 7.3 million in start-up cost financing for Cutanea’s redesigned business activities (“start-up costs”). These start-up costs are to be paid back to Maruho by the end of 2023 in accordance with contractual obligations related to an earn-out arrangement. In addition, as part of the earn-out arrangement with Maruho, the product profit amount from the sale of Cutanea products as defined in the share purchase agreement will be shared equally between Maruho and Biofrontera until 2030 (“contingent consideration”). In connection with this acquisition in 2019, we recorded the $ 7.3 million in start-up cost financing (See Note 24, Commitments and Contingencies- Cutanea payments 1.7 million contract asset related to the benefit associated with the non-interest bearing start-up cost financing and $ 6.5 million of contingent consideration related to the estimated profits from the sale of Cutanea products to be shared equally with Maruho. The contract asset related to the start-up cost financing is amortized on a straight-line basis using a 6.0 % interest rate over the 57 -month term of the financing arrangement, which ends on December 31, 2023 . The contract asset is shown net of the related start-up cost financing within acquisition contract liabilities, net. The contingent consideration was recorded at acquisition-date fair value using a Monte Carlo simulation with an assumed discount rate of 6.0 % over the applicable term. The contingent consideration is recorded within acquisition contract liabilities, net. The amount of contingent consideration that could be payable is not subject to a cap under the agreement. The Company re-measures contingent consideration and re-assesses the underlying assumptions and estimates at each reporting period utilizing a scenario-based method. Acquisition contract liabilities, net consist of the following: Schedule of Acquisition Contract Liabilities (in thousands) December 31, December 31, Short-term acquisition contract liabilities: Start-up cost financing 7,300 3,600 Contract asset (358 ) (358 ) Acquisition contract liabilities, net $ 6,942 $ 3,242 Long-term acquisition contract liabilities: Contingent consideration $ 2,400 $ 6,200 Start-up cost financing - 3,700 Contract asset - (358 ) Acquisition contract liabilities, net $ 2,400 $ 9,542 Total acquisition contract liabilities: Contingent consideration $ 2,400 $ 6,200 Start-up cost financing 7,300 7,300 Contract asset (358 ) (716 ) Total acquisition contract liabilities, net $ 9,342 $ 12,784

Fair Value Measurements

Fair Value Measurements	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at June 30, 2023 and December 31, 2022 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Schedule of Fair Value Hierarchy Valuation Inputs (in thousands) Level June 30, 2023 December 31, 2022 Assets: Investment, related party 1 $ 5,935 $ 10,548 Liabilities: Contingent Consideration 3 $ 2,300 $ 2,400 Warrant liability – 2022 Purchase Warrants 3 $ 668 $ 1,129 Warrant liability - 2022 Inducement Warrants 3 $ 772 $ 1,714 Warrant liability 3 $ 772 $ 1,714 Investment, related party As of June 30, 2023 and December 31, 2022, the Company had 6,280,396 and 6,446,946 , respectively of common shares of Biofrontera AG, a significant shareholder. The fair value of this investment was determined with Level 1 inputs through references to quoted market prices. See Note 13, “ Related Party Transactions Contingent Consideration Contingent consideration, which relates to the estimated profits from the sale of Cutanea products to be shared equally with Maruho, is reflected at fair value within acquisition contract liabilities, net on the consolidated balance sheets. The fair value is based on significant inputs not observable in the market, which represent a Level 3 measurement within the fair value hierarchy. The valuation of the contingent consideration utilizes a scenario-based method under which a set of payoffs are calculated using the term of the earnout, projections, and an appropriate metric risk premium. These payoffs are then discounted back from the payment date to the valuation date using a payment discount rate. Finally, the discounted payments are summed together to arrive at the value of the contingent consideration. The scenario-based method incorporates the following key assumptions: (i) the forecasted product profit amounts, (ii) the remaining contractual term, (iii) a metric risk premium, and (iv) a payment discount rate. The Company re-measures contingent consideration and re-assesses the underlying assumptions and estimates at each reporting period. The following table provides a roll forward of the fair value of the contingent consideration: Schedule of Fair Value of Contingent Consideration (in thousands) Balance at December 31, 2022 $ 2,400 Change in fair value of contingent consideration (100 ) Balance at June 30, 2023 $ 2,300 Balance at December 31, 2021 $ 6,200 Change in fair value of contingent consideration (1,900 ) Balance at June 30, 2022 $ 4,300 Warrant Liabilities The warrant liabilities are comprised of (i) a warrant to purchase 170,950 shares of common stock issued in a private placement on May 16, 2022, expiring five and one-half years after the issue date and with an exercise price of $ 55.40 per share (the “Purchase Warrants”) and (ii) a warrant to purchase 214,286 shares of common stock issued on July 26, 2022, expiring on December 1, 2026 with an exercise price of $ 33.20 per share (the “Inducement Warrants”), were accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities in the accompanying consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within the consolidated statements of operations. The Company utilizes a Black-Scholes option pricing model to estimate the fair value of the Purchase Warrants and Inducement Warrants which is considered a Level 3 fair value measurement. Certain inputs utilized in our Black-Scholes pricing model may fluctuate in future periods based upon factors which are outside of the Company’s control. A significant change in one or more of these inputs used in the calculation of fair value may cause a significant change to the fair value of our warrant liabilities which could also result in material non-cash gain or loss being reported in our consolidated statements of operations. The fair value at June 30, 2023 was estimated using a Black-Scholes pricing model based on the following assumptions: Schedule of Fair Value Warrant by Using Black-Scholes Pricing Model Assumptions Purchase Inducement Stock price $ 10.40 $ 10.40 Expiration term (in years) 4.38 3.42 Volatility 90.0 % 85.0 % Risk-free Rate 4.20 % 4.37 % Dividend yield 0.0 % 0.0 % The following table presents the changes in the warrant liabilities measured at fair value (in thousands): Schedule of Changes in Fair Value Warrant Liabilities 2023 2022 Six Months Ended June 30, 2023 2022 Fair value at beginning of period $ 2,843 $ 12,854 Issuance of new derivative liabilities - 9,274 Change in fair value of warrant liability (1,403 ) (14,082 ) Fair value at end of period $ 1,440 $ 8,046	4. Fair Value Measurements The following table presents information about the Company’s assets that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Schedule of Fair Value Hierarchy Valuation Inputs (in thousands) Level December 31, 2022 December 31, 2021 Assets: Investment, related party 1 $ 10,548 $ - Liabilities: Contingent Consideration 3 $ 2,400 $ 6,200 Warrant liability – 2021 Purchase Warrants 3 $ - $ 12,854 Warrant liability – 2022 Purchase Warrants 3 $ 1,129 $ - Warrant liability - Purchase Warrants 3 $ 1,129 $ - Warrant liability – 2022 Inducement Warrants 3 $ 1,714 $ - Warrant liability 3 $ 1,714 $ - Investment, related party As of December 31, 2022, the Company had investments in common stock of Biofrontera AG, a significant shareholder. The fair value of these investments was determined with Level 1 inputs through references to quoted market prices. Contingent Consideration Contingent consideration, which relates to the estimated profits from the sale of Cutanea products to be shared equally with Maruho, is reflected at fair value within acquisition contract liabilities, net on the consolidated balance sheets. The fair value is based on significant inputs not observable in the market, which represent a Level 3 measurement within the fair value hierarchy. The valuation of the contingent consideration utilizes a scenario-based method under which a set of payoffs are calculated using the term of the earnout, projections, and an appropriate metric risk premium. These payoffs are then discounted back from the payment date to the valuation date using a payment discount rate. Finally, the discounted payments are summed together to arrive at the value of the contingent consideration. The scenario-based method incorporates the following key assumptions: (i) the forecasted product profit amounts, (ii) the remaining contractual term, (iii) a metric risk premium, and (iv) a payment discount rate. The Company re-measures contingent consideration and re-assesses the underlying assumptions and estimates at each reporting period. The following table provides a roll forward of the fair value of the contingent consideration: Schedule of Fair Value of Contingent Consideration (in thousands) Balance at December 31, 2020 $ 7,602 Change in fair value of contingent consideration (1,402 ) Balance at December 31, 2021 $ 6,200 Change in fair value of contingent consideration (3,800 ) Balance at December 31, 2022 $ 2,400 The decrease in fair value of the contingent consideration in the amount of $ (3.8) (1.4) Warrant Liabilities The Purchase and Inducement Warrants were accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities in the accompanying consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within the consolidated statement of operations. Given the nominal strike price of $ 0.001 , the fair value of the Pre-funded Warrant was deemed to be equal to the market price of the underlying common stock at issuance and at each reporting period and is considered a level 2 liability. The Pre-funded Warrant was issued and exercised within the same year and therefore is not reflected in the ending balance. The Company utilizes a Black-Scholes option pricing model to estimate the fair value of the Purchase and Inducement Warrants which is considered a Level 3 fair value measurement. Certain inputs utilized in our Black-Scholes pricing model may fluctuate in future periods based upon factors which are outside of the Company’s control. A significant change in one or more of these inputs used in the calculation of the fair value may cause a significant change to the fair value of our warrant liabilities which could also result in material non-cash gain or loss being reported in our consolidated statement of operations. The fair value at issuance was estimated using a Black-Scholes pricing model based on the following assumptions at December 1, 2021 for the 2021 Purchase Warrants, May 16, 2022 for the Purchase Warrants and July 26, 2022 for the Inducement Warrants: Schedule of Fair Value Warrant by Using Black-Scholes Pricing Model Assumptions 2021 Purchase Purchase Inducement Stock price $ 86.60 $ 52.40 $ 32.80 Expiration term (in years) 5 5.50 4.34 Volatility 60.0 % 65.0 % 70.0 % Risk-free Rate 1.15 % 2.83 % 2.84 % Dividend yield 0.0 % 0.0 % 0.0 % The fair value was estimated using Black-Scholes pricing model based on the following assumptions as of December 31, 2021: 2021 Purchase Stock price $ 150.40 Expiration term (in years) 4.92 Volatility 60.0 % Risk-free Rate 1.25 % Dividend yield 0.0 % The fair value was estimated using Black-Scholes pricing model based on the following assumptions as of December 31, 2022 (outstanding warrants were all issued during 2022): Purchase Inducement Stock price $ 18.40 $ 18.40 Expiration term (in years) 4.88 3.92 Volatility 70 % 75 % Risk-free Rate 3.96 % 4.07 % Dividend yield 0.0 % 0.0 % Dividend yield 0.0 % 0.0 % The following table presents the changes in the warrant liabilities measured at fair value (in thousands): Schedule of Changes in Fair Value Warrant Liabilities December 31, 2022 December 31, 2021 Fair value at beginning of year $ 12,854 $ - Issuance of new warrants 13,217 12,261 Exercise of warrants (6,840 ) (12,208 ) Change in fair value of warrant liability (19,017 ) 12,801 Warrant inducement expense 2,629 - Fair value at end of year $ 2,843 12,854

Revenue

Revenue	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue	5. Revenue We generate revenue primarily through the sales of our licensed products Ameluz®, BF-RhodoLED® lamps and Xepi®. Revenue from the sales of our BF-RhodoLED® lamp and Xepi® are relatively insignificant compared with the revenues generated through our sales of Ameluz®. Related party revenue relates to an agreement with Biofrontera Bioscience GmbH (“Bioscience”) for BF-RhodoLED® leasing and installation service. Refer to Note 13, Related Party Transactions An analysis of the changes in product revenue allowances and reserves is summarized as follows: Schedule of Revenue Allowance and Accrual Activities (in thousands): Returns Co-pay assistance program Prompt pay discounts Government and payor rebates Total Balance at December 31, 2021 $ 43 $ 101 $ 48 $ 54 $ 246 Provision related to current period sales 5 380 11 129 525 Credit or payments made during the period (5 ) (300 ) (20 ) (115 ) (440 ) Balance at June 30, 2022 $ 43 $ 181 $ 39 $ 68 $ 331 Balance at December 31, 2022 $ 48 $ 9 $ 5 $ 20 $ 82 Beginning Balance $ 48 $ 9 $ 5 $ 20 $ 82 Provision related to current period sales 3 62 3 134 202 Credit or payments made during the period - (71 ) (2 ) (59 ) (132 ) Balance at June 30, 2023 $ 51 - 6 95 152 Ending Balance $ 51 - 6 95 152	5. Revenue We generate revenue primarily through the sales of our products Ameluz ® ® ® ® ® ® Related party revenue relates to an agreement with Biofrontera Bioscience GmbH (“Bioscience”) for BF-RhodoLED ® Note 17, Related Party Transactions An analysis of the changes in product revenue allowances and reserves is summarized as follows: Schedule of Revenue Allowance and Accrual Activities Co-pay Prompt Government assistance pay and payor (in thousands): Returns program discounts rebates Total Balance at December 31, 2020 $ 217 $ 52 $ 15 $ 43 $ 327 Provision related to current period sales 6 423 40 168 637 Credit or payments made during the period (180 ) (374 ) (7 ) (157 ) (718 ) Balance at December 31, 2021 $ 43 $ 101 $ 48 $ 54 $ 246 Provision related to current period sales 10 574 19 210 813 Credit or payments made during the period (5 ) (666 ) (62 ) (244 ) (977 ) Balance at December 31, 2022 $ 48 $ 9 $ 5 $ 20 $ 82

Investment, Related Party

Investment, Related Party	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Investments, All Other Investments [Abstract]
Investment, Related Party	6. Investment, Related Party As of June 30, 2023 and December 31, 2022, our investment in equity securities consisted solely of 6,280,396 and 6,446,946 , respectively of common shares of Biofrontera AG, a significant shareholder. See Note 13. Related Party Transactions 3,377,346 are not fully in our control to vote or dispose of as we see fit as they are not held in a brokerage account registered in our name, however, we are currently engaged with advisors to transfer such shares to our brokerage account. Equity securities gains and losses include unrealized gains and losses from changes in fair values during the period on equity securities we still own, as well as gains and losses on securities we sold during the period. As reflected in the consolidated statements of cash flows, we received proceeds from sales of equity securities of approximately $ 0.2 million during the six months ended June 30, 2023. Unrealized gains and losses on investment, related party are summarized as follows: Schedule of Unrealized Gains and Losses on Investments in Equity Securities (in thousands) 2023 2022 2023 2022 Three months ended Six months ended (in thousands) 2023 2022 2023 2022 Net losses recognized during the period on equity securities $ (1,482 ) $ - $ (4,424 ) $ - Less: Net losses recognized during the period on equity securities sold 75 - 75 - Unrealized losses recognized during the reporting period on equity securities still held at the reporting date $ (1,407 ) $ - $ (4,349 ) $ -	6. Investment, Related Party On October 25, 2022, the Company entered into private exchange agreements with certain holders of options to acquire common shares, nominal value € 1.00 per share, of Biofrontera AG (“AG Options), a German stock corporation and significant shareholder of the Company, pursuant to which the parties agreed to a negotiated private exchange of 157,042 shares of the Company’s common stock in exchange for the AG Options. There was no additional cost to exercise the AG Options. On November 8, 2022, the Company exercised the AG options in full to acquire 2,623,365 shares of Biofrontera AG. In addition, the Company purchased an additional 3,843,581 common shares of Biofrontera AG for a total of 6,446,946 shares or approximately 10 % of Biofrontera AG’s outstanding common shares as of December 31, 2022. . Equity securities gains and losses include unrealized gains and losses from changes in fair values during the period on equity securities we still own, as well as gains and losses on securities we sold during the period. There were no proceeds from sales of equity securities during the twelve months ended December 31, 2022. Unrealized gains and losses on investment, related party are summarized as follows: Schedule of Unrealized Gains and Losses on Investments in Equity Securities (in thousands) 2023 2022 2023 2022 Three months ended Six months ended (in thousands) 2023 2022 2023 2022 Net losses recognized during the period on equity securities $ (1,482 ) $ - $ (4,424 ) $ - Less: Net losses recognized during the period on equity securities sold 75 - 75 - Unrealized losses recognized during the reporting period on equity securities still held at the reporting date $ (1,407 ) $ - $ (4,349 ) $ -

Accounts Receivable, net

Accounts Receivable, net	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Credit Loss [Abstract]
Accounts Receivable, net	7. Accounts Receivable, net Accounts receivables are mainly attributable to the sale of Ameluz ® The allowance for credit losses was $ 0.2 million and $ 0.1 million as of June 30, 2023 and December 31, 2022, respectively.	7. Accounts Receivable, net Accounts receivable are mainly attributable to the sale of Ameluz ® ® ® The allowance for doubtful accounts was $ 0.1 million and negligible as of December 31, 2022 and 2021, respectively.

Other Receivables, Related Part

Other Receivables, Related Party	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Receivables [Abstract]
Other Receivables, Related Party	8. Other Receivables, Related Party As of June 30, 2023 the Company has a receivable of $ 4.0 million due from related parties of which $ 3.7 million is due from Biofrontera AG for its 50 % share of the balance of a legal settlement (see Note 18. Commitments and Contingencies – Legal proceedings 6.0 % per annum for each day that any reimbursement is past due and the ability to offset any overdue reimbursement amounts against payments owed to Biofrontera AG by the Company (including amounts owed under the Company’s license and supply agreement for Ameluz ®	8. Other Receivables, Related Party As of December 31, 2022, the Company has a receivable of $ 6.5 million ($ 3.7 short term and $ 2.8 long-term) due from the Biofrontera Group of which $ 6.4 million is due from Biofrontera AG for its 50 % share of the balance of a legal settlement for which both parties are jointly and severally liable (refer to Note 24 Commitments and Contingencies 11.3 million, with $ 2.8 million in long-term. The Company has a contractual right to repayment of its share of the settlement payments, plus interest and other miscellaneous settlement costs, from Biofrontera AG under the Settlement Allocation Agreement entered into on December 9, 2021 and as amended on March 31, 2022, which provides that the settlement payments would first be made by the Company and then reimbursed by Biofrontera AG for its share. The March 31, 2022 Amended Settlement Allocation Agreement provides certain remedies to the Company, if Biofrontera AG fails to make timely reimbursements, which the Company may implement in its sole discretion, including the ability to charge interest at a rate of 6.0 % per annum for each day that any reimbursement is past due and the ability to offset any overdue reimbursement amounts against payments owed to Biofrontera AG by the Company (including amounts owed under the Company’s license and supply agreement for Ameluz ®

Inventories

Inventories	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventories	9. Inventories Inventories are comprised of Ameluz ® ® ® The provision related to BF-RhodoLED ® 0.1 million for the year ended December 31, 2022, and negligible for the year ended December 31, 2021. The provision for Xepi ® 0.3 million for the year ended December 31, 2021. no

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2022
Prepaid Expenses And Other Current Assets
Prepaid Expenses and Other Current Assets	10. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets (in thousands) December 31, December 31, Receivable for common stock warrants proceeds $ - $ 3,258 Prepaid expenses 439 $ 824 Security deposits 85 149 Other 286 756 Total $ 810 $ 4,987

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	11. Property and Equipment, Net Property and equipment, net consists of the following: Schedule of Property and Equipment (in thousands) December 31, December 31, Computer equipment $ 89 $ 85 Computer software 27 27 Furniture & fixtures 81 81 Leasehold improvement 368 368 Machinery & equipment 146 112 Property and equipment, gross 711 673 Less: Accumulated depreciation (507 ) (406 ) Property and equipment, net $ 204 $ 267 Depreciation expense was $ 0.1 million for each of the years ended December 31, 2022, and 2021, respectively, which was included in selling, general and administrative expense on the consolidated statements of operations.

Intangible Asset, Net

Intangible Asset, Net	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Asset, Net	9. Intangible Asset, Net Intangible asset, net consists of the following: Schedule of Intangible Asset Net (in thousands) June 30, 2023 December 31, 2022 Xepi® license $ 4,600 $ 4,600 Less: Accumulated amortization (1,777 ) (1,568 ) Intangible asset, net $ 2,823 $ 3,032 The Xepi® license intangible asset was recorded at acquisition-date fair value of $ 4.6 million and is amortized on a straight-line basis over the useful life of 11 years. Amortization expense for the three months ended June 30, 2023 and 2022 was $ 0.1 million and $ 0.2 million for the six months ended June 30, 2023 and 2022. We review the Xepi ® The Company did not recognize any impairment charges during the three and six months ended June 30, 2023 and 2022.	12. Intangible Asset, Net Intangible asset, net consists of the following: Schedule of Intangible Asset Net (in thousands) December 31, December 31, Xepi ® $ 4,600 $ 4,600 Less: Accumulated amortization (1,568 ) (1,150 ) Intangible asset, net $ 3,032 $ 3,450 The Xepi ® 4.6 million and is amortized on a straight-line basis over the useful life of 11 years. Amortization expense was $ 0.4 million for each the years ended December 31, 2022 and 2021. We review the Xepi ® ® ®

Cash Balances and Statement of

Cash Balances and Statement of Cash Flows Reconciliation	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
Cash Balances and Statement of Cash Flows Reconciliation	10. Cash Balances and Statement of Cash Flows Reconciliation The Company maintains its cash balances at financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”). The FDIC provides coverage of up to $ 250,000 4.2 Restricted cash consists primarily of deposits of cash collateral held in accordance with the terms of our corporate credit cards. The following table provides a reconciliation of cash, cash equivalents, and restricted cash that sum to the total shown in the consolidated statements of cash flows: Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (in thousands) June 30, 2023 December 31, 2022 Cash and cash equivalents $ 4,453 $ 17,208 Long-term restricted cash 200 200 Total cash, cash equivalent, and restricted cash shown on the consolidated statements of cash flows $ 4,653 $ 17,408	13. Statement of Cash Flows Reconciliation Cash Balances and Statement of Cash Flows Reconciliation The following table provides a reconciliation of cash, cash equivalents, and restricted cash that sum to the total shown in the statements of cash flows: Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (in thousands) December 31, December 31, Cash and cash equivalents $ 17,208 $ 24,545 Short-term restricted cash - 47 Long-term restricted cash 200 150 Total cash and cash equivalent, and restricted cash shown on the statements of cash flows $ 17,408 $ 24,742 Short-term and long-term restricted cash were recorded in prepaid expenses and other current assets, and other assets, respectively, in the consolidated balance sheet.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	11. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following: Schedule of Accrued Expenses and Other Current Liabilities (in thousands) June 30, 2023 December 31, 2022 Legal settlement (See note 18) $ 6,094 $ 6,207 Employee compensation and benefits 2,816 2,850 Professional fees 1,163 1,353 Product revenue allowances and reserves 152 82 Other 511 372 Total $ 10,736 $ 10,864	14. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following: Schedule of Accrued Expenses and Other Current Liabilities (in thousands) December 31, December 31, Legal settlement (See Note 24) $ 6,207 $ 5,625 Employee compensation and benefits 2,850 2,384 Professional fees 1,353 570 Product revenue allowances and reserves 82 246 Other 372 829 Total $ 10,864 $ 9,654

Other Long-Term Liabilities

Other Long-Term Liabilities	12 Months Ended
	Dec. 31, 2022
Other Liabilities Disclosure [Abstract]
Other Long-Term Liabilities	15. Other Long-Term Liabilities Other long-term liabilities consist of the following: Schedule of Other Long Term Liabilities (in thousands) December 31, December 31, Legal settlement – noncurrent (See Note 24) $ - $ 5,625 Other 21 24 Total $ 21 $ 5,649

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	16. Income Taxes As a result of the net losses, we have incurred in each fiscal year since inception, we have recorded no provision for federal income taxes for the years ended December 31, 2022 and December 31, 2021. Income tax expense incurred in 2022 and 2021 relates to state income taxes. At December 31, 2022 and December 31, 2021, the Company had no unrecognized tax benefits. A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company’s effective income tax rate is as follows: Schedule of Effective Income Tax Rate Reconciliation 2022 2021 Year ended December 31, 2022 2021 Income tax computed at federal statutory tax rate 21.00 % 21.00 % State taxes (5.85 )% (0.09 )% Permanent differences – non-deductible expenses (37.93 )% (1.03 )% Change in fair value of contingent consideration 133.62 % 0.78 % Change in fair value of warrant liabilities 576.27 % (7.13 )% True-ups (7.42 )% - Change in valuation allowance (685.54 )% (13.62 )% Effective income tax rate (5.85 )% (0.09 )% The principal components of the Company’s deferred tax assets and liabilities consist of the following at December 31, 2022 and 2021: Schedule of Deferred Tax Assets and Liabilities (in thousands) December 31, December 31, Deferred tax assets (liabilities): Net operating loss carryforwards $ 30,450 $ 24,307 Intangible assets 4,824 5,132 Acquisition contract liabilities (96 ) (187 ) Property and equipment 123 103 Accrued expenses and reserves 890 1,693 Stock based compensation 449 - Lease liability 361 - Other - 6 ROU asset (369 ) - Investment revaluation (469 ) - Total deferred tax assets 36,163 31,054 Less valuation allowance (36,163 ) (31,054 ) Net deferred taxes $ - $ - The Company has had no federal income tax expense due to operating losses incurred since inception. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on this, the Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the deferred tax assets is not determined to be more likely than not. During 2022, the valuation allowance increased by $ 5.1 million, primarily due to the increase in the Company’s net operating loss carryforwards during the period. As of December 31, 2022, the Company had approximately $ 123.4 million and $ 89.2 million of Federal and state net operating loss carryforwards, respectively. $ 113.8 million of the federal NOLs are not subject to expiration and the remaining NOLs begin to expire in 2036. These loss carryforwards are available to reduce future federal taxable income, if any. These loss carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. The amount of loss carryforwards that may be utilized in any future period may be limited based upon changes in the ownership of the Company’s shareholders. The Company follows the provisions of ASC 740-10, “Accounting for Uncertainty in Income Taxes,” which specifies how tax benefits for uncertain tax positions are to be recognized, measured, and recorded in financial statements; requires certain disclosures of uncertain tax matters; specifies how reserves for uncertain tax positions should be classified on the balance sheet; and provides transition and interim period guidance, among other provisions. As of December 31, 2022, the Company has not recorded any amounts for uncertain tax positions. The Company’s policy is to recognize interest and penalties accrued on any uncertain tax positions as a component of income tax expense, if any, in its statements of operations. As of December 31, 2022 the Company had no reserves for uncertain tax positions. For the year ended December 31, 2022 no estimated interest or penalties were recognized on uncertain tax positions. The Company’s tax returns 2019 through 2022 remain open and subject to examination by the Internal Revenue Service and state taxing authorities. Net operating loss carryovers from earlier years are also subject to exam and adjustment.

Related Party Transactions

Related Party Transactions	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	13. Related Party Transactions License and Supply Agreement On October 8, 2021, we entered into an amendment to the Ameluz LSA under which the price we pay per unit will be based upon our sales history. As a result of this amendment, the purchase price we pay the Ameluz Licensor for Ameluz ® ● fifty percent of the anticipated net price per unit until we generate $ 30 million in revenue from sales of the products we license from the Ameluz Licensor during a given Commercial Year (as defined in the Ameluz LSA); ● forty percent of the anticipated net price per unit for all revenues we generate between $ 30 million and $ 50 million from sales of the products we license from the Ameluz Licensor; and ● thirty percent of the anticipated net price per unit for all revenues we generate above $ 50 million from sales of the products we license from the Ameluz Licensor. Under the agreement, the Company obtained an exclusive, non-transferable license to use Pharma’s technology to market and sell the licensed products, Ameluz ® ® Purchases of the licensed products during the three and six months ended June 30, 2023 were $ 10.4 million and $ 13.7 million, respectively, and $ 6.2 million and $ 11.5 million, respectively for the three and six months ended June 30, 2022. The purchases were recorded in inventories in the consolidated balance sheets, and, when sold, in cost of revenues, related party in the consolidated statements of operations. Amounts due and payable to Pharma as of June 30, 2023 and December 31, 2022 were $ 4.7 million and $ 1.3 million, respectively, which were recorded in accounts payable, related parties in the consolidated balance sheets. Service Agreements In December 2021, we entered into an Amended and Restated Master Contract Services Agreement, or “Services Agreement”, which provides for the execution of statements of work that will replace the applicable provisions of our previous intercompany services agreement dated January 1, 2016, or 2016 Services Agreement, by and among us, Biofrontera AG, Biofrontera Pharma and Biofrontera Bioscience, enabling us to continue to use the IT resources of Biofrontera AG and its wholly owned subsidiaries (the “Biofrontera Group”) as well as providing access to the Biofrontera Group’s resources with respect to quality management, regulatory affairs and medical affairs. We currently have statements of work in place regarding IT, regulatory affairs, medical affairs, and pharmacovigilance, and are continuously assessing the other services historically provided to us by Biofrontera AG to determine 1) if they will be needed, and 2) whether they can or should be obtained from other third-party providers. As of June 30, 2023, we have migrated away from Biofrontera AG to third party providers for most of our significant IT services. Expenses related to the service agreement were $ 0.1 million for the three and six months ended June 30, 2023 and $ 0.3 million and $ 0.4 million for the three and six months ended June 30, 2022, respectively. These expenses were recorded in selling, general and administrative, related party. Amounts due to Biofrontera AG related to the service agreement as of June 30, 2023 and December 31, 2022 were $ 0.2 million and $ 0.2 million, respectively, which were offset against other receivables, related party in the consolidated balance sheet. Clinical Lamp Lease Agreement On August 1, 2018, the Company executed a clinical lamp lease agreement with Biofrontera Bioscience GmbH (“Bioscience”) to provide lamps and associated services. Total revenue related to the clinical lamp lease agreement was minimal for the three and six months ended June 30, 2023 and 2022, and was recorded as revenues, related party. Amounts due from Bioscience for clinical lamp and other reimbursements were approximately $ 0.5 million and $ 0.1 as of June 30, 2023 and December 31, 2022, respectively, which were recorded as other receivables, related party in the consolidated balance sheets. Others The Company has recorded a receivable of $ 3.7 million and $ 6.4 million as of June 30, 2023 and December 31, 2022, respectively, due from Biofrontera AG for its 50 % share of the balance of a legal settlement for which both parties are jointly and severally liable. See Note 8. Other Receivables, Related Party no interest income recognized for the six months ended June 30, 2023 and $ 0.1 million of interest income for the six months ended June 30, 2022, in connection with this receivable. As of June 30, 2023, our investment, related party is valued at $ 5.9 million and consists of 6,280,396 common shares of Biofrontera AG, a significant shareholder of the Company. Of these shares, 3,377,346 are not fully in our control to vote or dispose of as we see fit as they are not held in a brokerage account registered in our name, however, we are currently engaged with advisors to transfer such shares to our brokerage account.	17. Related Party Transactions License and Supply Agreement On October 8, 2021, we entered into an amendment to the Ameluz LSA under which the price we pay per unit will be based upon our sales history. As a result of this amendment, the purchase price we pay the Ameluz Licensor for Ameluz ® ● fifty percent of the anticipated net price per unit until we generate $ 30 million in revenue from sales of the products we license from the Ameluz Licensor during a given Commercial Year (as defined in the Ameluz LSA); ● forty percent of the anticipated net price per unit for all revenues we generate between $ 30 million and $ 50 million from sales of the products we license from the Ameluz Licensor; and ● thirty percent of the anticipated net price per unit for all revenues we generate above $ 50 million from sales of the products we license from the Ameluz Licensor. Under the agreement, the Company obtained an exclusive, non-transferable license to use Pharma’s technology to market and sell the licensed products, Ameluz ® ® Purchases of the licensed products from Pharma during the years ended December 31, 2022 and 2021 were $ 16.6 million and $ 9.4 million, respectively, and recorded in inventories in the consolidated balance sheets, and, when sold, in cost of revenues, related party in the consolidated statements of operations. Amounts due and payable to Pharma as of December 31, 2022 and 2021 were $ 1.3 million and $ 0.3 million, respectively, which were recorded in accounts payable, related parties in the consolidated balance sheets. Service Agreements In December 2021, we entered into an Amended and Restated Master Contract Services Agreement, or “Services Agreement”, which provides for the execution of statements of work that will replace the applicable provisions of our previous intercompany services agreement dated January 1, 2016, or 2016 Services Agreement, by and among us, Biofrontera AG, Biofrontera Pharma and Biofrontera Bioscience, enabling us to continue to use the IT resources of Biofrontera AG and its wholly owned subsidiaries (the “Biofrontera Group”) as well as providing access to the Biofrontera Group’s resources with respect to quality management, regulatory affairs and medical affairs. We currently have statements of work in place regarding IT, regulatory affairs, medical affairs, pharmacovigilance, and investor relations services, and are continuously assessing the other services historically provided to us by Biofrontera AG to determine 1) if they will be needed, and 2) whether they can or should be obtained from other third-party providers. Expenses related to the service agreement were $ 0.7 million and $ 0.7 million for the years ended December 31, 2022 and 2021, which were recorded in selling, general and administrative, related party. Amounts due to Biofrontera AG related to the service agreement were $ 0.2 million as of December 31, 2022 and 2021, which were recorded in accounts payable, related parties in the consolidated balance sheets. Clinical Lamp Lease Agreement On August 1, 2018, the Company executed a clinical lamp lease agreement with Biofrontera Bioscience GmbH (“Bioscience”) to provide lamps and associated services. Total revenue related to the clinical lamp lease agreements was approximately $ 0.1 million for each of the years ended December 31, 2022 and 2021 and recorded as revenues, related party. Amounts due from Bioscience for clinical lamp and other reimbursements were approximately $ 0.1 million for each of the years ended December 31, 2022 and 2021, which were recorded as accounts receivable, related party in the consolidated balance sheets. Reimbursements from Maruho Related to Cutanea Acquisition Pursuant to the Cutanea acquisition share purchase agreement, we received start-up cost financing and reimbursements for certain costs. These restructuring costs Maruho agreed to pay are referred to as “SPA costs” under the arrangement and are to be accounted for as other income. There were no amounts reimbursed relating to SPA costs for the year ended December 31, 2022. For the year ended December 31, 2021 the amounts reimbursed relating to SPA costs were $ 0.5 million and were recorded as other income in the consolidated statements of operations as the related expenses were incurred. There were no amounts due from Maruho for the year ended December 31, 2022. The amounts due from Maruho, primarily relating to SPA cost reimbursements, were $ 0.1 million as of December 31, 2021 and were recorded in other receivables, related parties in the consolidated balance sheets. Others The Company has recorded a receivable of $ 6.4 million and $ 11.3 million as of December 31, 2022 and December 31, 2021 due from Biofrontera AG for its 50 % share of the balance of a legal settlement for which both parties are jointly and severally liable as of December 31, 2022. Refer to Note 8, Other Receivables, Related Party 0.1 and $ 0.0 million of interest income for the years ended December 31, 2022 and 2021, respectively in connection with this receivable. As of December 31, 2022, our investment, related party valued at $ 10.5 million consists of 6,466,949 common shares of Biofrontera AG, a significant shareholder. See Note 6. In accordance with a Share Purchase and Transfer Agreement dated, November 3, 2022, the Company purchased approximately 1,674,996 shares (of the total 6,466,946 shares) for $ 1.7 million from Maruho.

Restructuring costs

Restructuring costs	12 Months Ended
	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Restructuring costs	18. Restructuring costs We restructured the business of Cutanea and incurred restructuring costs which are subsequently reimbursed by Maruho. Restructuring costs primarily relate to the winding down of Cutanea’s operations. There were no restructuring costs for the year ended December 31, 2022. For the year ended December 31, 2021, restructuring costs were incurred in the amount of $ 0.8 million, of which $ 0.5 million had been reimbursed in 2021.

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Equity [Abstract]
Stockholders’ Equity	14. Stockholders’ Equity Under the Company’s amended and restated certificate of incorporation, dated December 21, 2020, the Company is authorized to issue 15,000,000 shares of common stock, par value $ 0.001 per share and 20,000,000 shares of preferred stock, par value $ .001 per share. See Note 20. Subsequent Events The holders of common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors. The Company has not declared dividends since inception. In the event of liquidation of the Company, dissolution or winding up, the holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities. The common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the common stock. The outstanding shares of common stock are fully paid and non-assessable.	19. Stockholders’ Equity Under the Company’s amended and restated certificate of incorporation, dated December 21, 2020, the Company is authorized to issue 15,000,000 shares of common stock, par value $ 0.001 per share and 20,000,000 shares of preferred stock, par value $ 0.001 Note 2. Summary of Significant Accounting Policies Note 26. Subsequent Events The holders of common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors. The Company has not declared dividends since inception. In the event of liquidation of the Company, dissolution or winding up, the holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities. The common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the common stock. The outstanding shares of common stock are fully paid and non-assessable. Initial Public Offering. 180,000 units (“Units”) each consisting of (i) one share of common stock of the Company, par value $ 0.001 per share and (ii) one warrant (the “IPO Warrants”). Every 20 warrants will be exercisable for one share of Common Stock at an exercise price of $ 100.00 per share of Common Stock. The IPO Warrants are immediately exercisable upon issuance for a period of five years after the issuance date. The common stock shares and Warrants were issued separately in the offering and may be transferred separately immediately upon issuance. The Units were sold at a price of $ 100.00 per Unit, with gross proceeds from the IPO of approximately $ 18 million, offset by $ 3.1 million in offering costs. At the IPO date, the underwriters also exercised in full their option to purchase up to an additional 27,000 IPO Warrants at the purchase price of $ 0.20 per Warrant to cover over-allotments. In connection with the IPO, the Company also issued to the underwriters Unit Purchase Options (“UPO”) to purchase, in the aggregate, (a) 5,400 Units and (b) 810 Warrants (relating to the underwriters’ exercise of the over-allotment option in full, with respect to the Warrants). The UPOs have an exercise price of $ 125.00 if exercisable for Units and $ 0.25 if exercisable for Warrants. The UPOs are exercisable at any time from October 28, 2021 (“Effective Date”) through the 5 th The UPOs issued to the underwriters were accounted for as equity under ASC 718, Compensation -Stock Compensation (“ASC 718”). The fair value of the UPOs, which were fully vested at the issuance date, was recognized as an offering cost against the proceeds from the IPO. The estimated fair value of the UPO Units of $ 0.3 million at the IPO date was determined using a Black-Scholes option pricing model with the following assumptions: fair value of the underlying unit of $ 99 , expected volatility of 60.0 %, risk free rate of 1.15 %, remaining contractual term of 5 years and a dividend yield of 0 %. The estimated fair value of the UPO Warrants of $ 21,000 at the IPO date was determined using a Black-Scholes option pricing model with the following assumptions: fair value of the underlying unit of $ 25.80 , expected volatility of 60.0 %, risk free rate of 1.15 %, remaining contractual term of 5 years and a dividend yield of 0 %. Private Placement – 15,000,000 67,500 142,857 75,357 105.00 0.002 105.00 104.80 On December 28, 2021, 75,357 common stock shares were issued from the exercise of the Pre-Funded Warrant at an exercise price of $ 0.002 per share of the Company’s common stock. In connection with the December 2021 PIPE, the Company, issued Unit Purchase Options (“PP-UPO”) to the placement agents to purchase, in the aggregate, (a) 4,286 Units, consisting of one share of common stock and one warrant to purchase common stock. The PP-UPOs have an exercise price of $ 131.20 and are exercisable at any time for the period of 5 years. The PP-UPOs issued to the underwriters were accounted for under ASC 718, Compensation -Stock Compensation (“ASC 718”). The fair value of the PP-UPOs, which were fully vested at the issuance date, was recognized as an offering cost of the December 2021 PIPE and allocated between the issuance costs of warrants and issuance costs of common stock, based on the allocated proceeds. The Company estimated the fair value of the unit purchase options to be approximately $ 0.3 million at December 1, 2021 of which $ 0.2 million was allocated to the issuance costs of warrants and immediately expensed in the consolidated statement of operations and $ 0.1 million was allocated to the issuance costs of common stock and charged to equity. The fair value was determined using a Black-Scholes option pricing model with the following assumptions: fair value of the underlying unit of $ 127.80 , expected volatility of 60.0 %, risk free rate of 1.15 %, remaining contractual term of 5 years and a dividend yield of 0 %. Private Placement – 9.4 million (i) 92,500 shares of the common stock, (ii) a warrant to purchase up to 170,950 shares of the common stock (“2022 Purchase Warrant”) and (iii) a warrant to purchase up to 78,450 shares of the common stock (“2022 Pre-Funded Warrant”). The purchase price for one share of common stock (or common stock equivalent) and a warrant to purchase one share of common stock was $ 55.00 . The 2022 Purchase Warrant will be exercisable nine months after the issue date, expires five and one-half years after the issue date and has an exercise price of: $ 55.40 per share. The Pre-Funded Warrant is exercisable immediately and has a term of exercise equal to five ( 5 ) years with a nominal exercise price of $ 0.02 per share. Because the warrants are accounted for as liabilities, the May 2022 PIPE proceeds were allocated between the fair value of the warrants with the remaining proceeds allocated to common stock and additional paid in capital. Exercise of 2022 Pre-Funded Warrant - 78,450 shares of common stock at an exercise price of $ 0.02 Exercise of 2021 Purchase Warrant and Issuance of July 2022 Inducement Warrant - 142,858 shares of common stock, par value $ 0.001 per share. The Investor agreed to exercise for cash, the 2021 Purchase Warrants, in exchange for the Company’s agreement to (i) lower the exercise price of the 2021 Purchase Warrants from $ 105.00 to $ 32.40 per share and (ii) issue a new warrant (the “Inducement Warrant”) to purchase up to 214,286 shares of common stock. The Company received proceeds of $ 4.6 million, from the exercise of the 2021 Purchase Warrants and expensed the related issuance costs of $ 0.3 million. The modification expense associated with the change in fair value due to the repricing of the 2021 Purchase Warrants is recorded as inducement expense. The 2021 Purchase Warrant modification along with the fair value of the inducement warrants of $ 2.6 million was expensed as warrant inducement expense in the accompanying consolidated statement of operations for the year ended December 31, 2022. The Inducement Warrant is exercisable on or after January 27, 2023 at a price per share of $ 33.20 and expires on December 1, 2026 . Adoption of a stockholder rights plan. 0.001 per share, of the Company at a cash exercise price of $ 5.00 per Unit, subject to adjustment, under certain conditions. The complete terms of the Rights are set forth in the Stockholder Rights Agreement, dated October 13, 2022, between the Company and Computershare Trust Company, N.A, as Rights agent. While the stockholder rights plan described above (the “Rights Plan”) is effective immediately, the Rights would become exercisable only if a person or group, or anyone acting in concert with such a person or group, acquires beneficial ownership, as defined in the Rights Agreement, of 20% or more of the Company’s issued and outstanding common stock in a transaction not approved by the Company’s Board of Directors. The Rights Plan will expire on October 13, 2023. Note 26. Su bsequent Events – Settlement Agreement. Under the Rights Plan, a person or group who beneficially owned 20% or more of the Company’s outstanding Common Stock prior to the first public announcement of the Rights Plan on October 14, 2022 will not trigger the Rights so long as they do not acquire beneficial ownership of any additional shares of Common Stock at a time when they still beneficially own 20% or more of such Common Stock. Series A Junior Participating Cumulative Preferred Stock. 5,000 shares of Preferred Stock. The Certificate of Designations was filed with the Secretary of State of Delaware and became effective on October 13, 2022. Exchange Agreement 1.00 per share, of Biofrontera AG, a German stock corporation, pursuant to which the parties agreed to a negotiated private exchange, and closed on a series of private exchanges of 3,148,042 shares of the Company’s common stock in exchange for the AG Options. Warrants Schedule of Warrants Warrant - PIPE Warrant - IPO* Total Warrants Weighted Average Exercise Price Balance, December 31, 2020 - - - $ - Issued 218,214 207,000 425,214 102.57 Exercised (75,357 ) (132,380 ) (207,737 ) 100.14 Balance, December 31, 2021 142,857 74,620 217,477 99.69 Issued 463,686 - 463,686 35.77 Exercised (221,307 ) - (221,307 ) 20.92 Balance, December 31, 2022 385,236 74,620 459,856 $ 52.29 * Every 20 IPO warrants are exercisable for one share of Common Stock at an exercise price of $100.00 per share of Common Stock. For financial statement purposes, the warrant shares have been decreased by a factor of 20 to effectively reflect the 1-for-20 reverse stock split. Refer to Note 26. Subsequent Events – Reverse

Equity Incentive Plans and Shar

Equity Incentive Plans and Share-Based Payments	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Equity Incentive Plans and Share-Based Payments	15. Equity Incentive Plans and Share-Based Payments 2021 Omnibus Incentive Plan In 2021, our Board of Directors adopted and our shareholders approved, the 2021 Omnibus Incentive Plan (“2021 Plan). Under the original 2021 Plan, 137,500 shares are reserved and authorized for awards and the maximum contractual term is 10 years for stock options issued under the 2021 Plan. On December 12, 2022, the 2021 Plan was amended by our stockholders and the number of shares authorized for awards under the 2021 Plan was increased by 129,490 to 266,990 . As of June 30, 2023, there were 152,301 shares available for future awards under the amended 2021 Plan. See Note 20. Subsequent Events Non-qualified stock options We maintain the 2021 Plan for the benefit of our officers, directors and employees. Employee stock options granted under the 2021 Plan generally vest in equal annual installments over three years and are exercisable for a period of up to ten years from the grant date. Non-employee director options vest in equal monthly installments following the date of grant and will be fully vested on the one-year anniversary of the date of grant. All stock options are exercisable at a price as set by the Company at the time of the grant but shall not be less than the market value of the common shares underlying the option on the grant date. The Company recognizes the grant-date fair value of share-based awards granted as compensation expense on a straight-line basis over the requisite service period. The fair value of stock options is estimated at the time of grant using the Black-Scholes (“BSM”) option pricing model, which requires the use of inputs and assumptions such as the fair value of the underlying stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield. The Company elects to account for forfeitures as they occur. The fair value of each option was estimated on the date of the grant using the BSM option pricing model with the following assumptions: Schedule of Stock Options Assumptions Six Months Ended June 30, 2023 2022 Expected volatility 70 95 % 55 65 % Expected term (in years) 6.0 5.24 - 6.0 Risk-free interest rate 3.5 3.9 % 1.79 2.90 % Expected dividend yield 0.0 % 0.0 % Share-based compensation expense of approximately $ 0.2 million and $ 0.4 million was recorded in selling, general and administrative expenses on the accompanying consolidated statement of operations for the three and six months ended June 30, 2023, respectively and $ 0.2 million and $ 0.3 million for the three and six months ended June 30, 2022. Options outstanding and exercisable under the employee share option plan as of June 30, 2023 and a summary of option activity during the six months then ended is presented below. Schedule of Stock Option Activity Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (1) Outstanding at December 31, 2022 86,951 $ 62.16 Granted 22,477 $ 13.98 Exercised - $ - Canceled or forfeited (20,419 ) $ 54.14 Outstanding at June 30, 2023 89,009 $ 51.84 8.65 $ 13 Exercisable at June 30, 2023 26,042 $ 64.95 7.54 $ - (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at June 30, 2023. As of June 30, 2023, there was $1.4 million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately 2.1 years. Share-Based Compensation (RSUs) Restricted Stock Units (“RSUs”) will vest annually over two years, subject to the recipient’s continued service with the Company through the applicable vesting dates. The fair value of each RSU is estimated based on the closing market price of the Company’s common stock on the grant date. Share-based compensation expense of $ 0.1 million and $ 0.2 million for the RSUs for the three and six months ended June 30, 2023, respectively, and $ 0.4 million and $ 0.8 million for the three and six months ended June 30, 2022 and was recorded in selling, general and administrative expenses in the accompanying consolidated statements of operations. Schedule of Restricted Stock Units Shares Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Weighted Average Grant Date Fair Value Outstanding at December 31, 2022 17,176 $ $ 52.2 Awarded - $ $ - Vested (8,588 ) $ $ 52.2 Canceled or forfeited (3,817 ) $ $ - Outstanding at June 30, 2023 4,771 0.88 $ 50 $ 52.2 As of June 30, 2023, there was $ 0.2 million of unrecognized compensation cost related to unvested RSUs, which is expected to be recognized over a weighted-average period of approximately 0.9 years.	20. Equity Incentive Plans and Share-Based Payments 2021 Omnibus Incentive Plan In 2021, our Board of Directors adopted and our shareholders approved, the 2021 Omnibus Incentive Plan (“2021 Plan). Under the original 2021 Plan, 137,500 shares are reserved and authorized for awards and the maximum contractual term is 10 years for stock options issued under the 2021 Plan . On December 12, 2022, the 2021 Plan was amended by our stockholders and the number of shares authorized for awards under the 2021 Plan was increased by 129,490 to 266,990 . As of December 31, 2022, there were 154,359 shares available for future awards under the amended 2021 Plan. Non-qualified stock options We maintain the 2021 Plan for the benefit of our officers, directors and employees. Employee stock options granted under the 2021 Plan generally vest in equal annual installments over three years and are exercisable for a period of up to ten years from the grant date. Non-employee director options vest in equal monthly installments following the date of grant and will be fully vested on the one-year anniversary of the date of grant. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date. The Company recognizes the grant-date fair value of share-based awards granted as compensation expense on a straight-line basis over the requisite service period. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the fair value of the underlying stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield. The Company elects to account for forfeitures as they occur. The fair value of each option was estimated on the date of the grant using the BSM option pricing model with the following assumptions: Schedule of Stock Options Assumptions 2022 2021 Expected volatility 55 % - 70 % 55.0 % Expected term (in years) 5.24 - 6.0 6.0 Risk-free interest rate 1.34 % - 4.10 % 1.34 % Expected dividend yield 0.0 % 0.0 % The weighted average grant-date fair value of options granted during the years ended December 31, 2022 and 2021 was $ 29.28 49.55 Share-based compensation expense of approximately $ 0.8 million was recorded in selling, general and administrative expenses on the accompanying consolidated statement of operations for the year ended December 31, 2022. There was negligible share-based compensation expense for the year ended December 31, 2021. Options outstanding and exercisable under the employee share option plan as of December 31, 2022 and December 2021, and a summary of option activity during the year then ended is presented below. Schedule of Stock Option Activity Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (1) Outstanding at December 31, 2020 - $ - Granted 30,942 $ 95.40 Exercised - $ - Canceled or forfeited (205 ) $ 95.40 Outstanding at December 31, 2021 30,737 $ 95.40 9.94 $ 1,691 Granted 64,572 $ 48.20 Exercised - $ - Canceled or forfeited (8,358 ) $ 76.11 Outstanding at December 31, 2022 86,951 $ 62.16 9.27 $ 1 Exercisable at December 31, 2022 11,166 $ 85.48 8.99 $ - (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2022 and December 31, 2021. As of December 31, 2022, there was $ 2.2 million of unrecognized compensation cost related to unvested stock options held by employees and directors, which is expected to be recognized over a weighted-average period of approximately 2.3 years. Share-Based Compensation (RSUs) Restricted Stock Units (“RSUs”) will vest annually over two years, subject to the recipient’s continued service with the Company through the applicable vesting dates. The fair value of each RSU is estimated based on the closing market price of the Company’s common stock on the grant date. Share-based compensation expense of $ 1.0 million and $ 0.1 million for the RSUs was recorded in selling, general and administrative expenses in the accompanying consolidated statement of operations for the years ended December 31, 2022 and 2021. As of December 31, 2022, there was $ 0.6 million of unrecognized compensation cost related to unvested RSUs, which is expected to be recognized over a weighted-average period of approximately 1.4 years. The total fair value of shares vested during the years ended December 31, 2022 and 2021 was $ 0.8 million and $ 0.0 million, respectively. The following table summarizes the activity for RSUs during the year ended December 31, 2022 and December 31, 2021: Schedule of Restricted Stock Units Shares Weighted Average Grant Date Fair Value Outstanding balance at December 31, 2020 - $ - Granted 8,504 95.40 Issued - - Forfeited - - Outstanding balance at December 31, 2021 8,504 $ 95.40 Awarded 17,176 52.20 Issued (8,504 ) 95.40 Forfeited - - Outstanding balance at December 31, 2022 17,176 $ 52.20

Interest Expense, net

Interest Expense, net	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Interest Expense, net	16. Interest Expense, net Interest expense, net consists of the following: Schedule of Interest Expense For three months ended For six months ended (in thousands) 2023 2022 2023 2022 Interest expense $ (32 ) $ (3 ) $ (33 ) $ (7 ) Contract asset interest expense (89 ) (89 ) (179 ) (179 ) Interest income – related party 40 53 94 110 Interest income – other 2 1 4 5 Interest income 2 1 4 5 Interest expense, net $ (79 ) $ (38 ) $ (114 ) $ (71 ) Interest expense is comprised primarily of interest on our Loan and Security Agreement with MidCap Business Credit LLC. Contract asset interest expense relates to the $ 1.7 million contract asset in connection with the $ 7.3 million start-up cost financing received from Maruho under the Cutanea acquisition share purchase agreement. The contract asset is amortized on a straight-line basis using a 6 % interest rate over the financing arrangement contract term, which ends on December 31, 2023 .	21. Interest Expense, net Interest expense, net consists of the following: Schedule of Interest Expense For years ended December 31, (in thousands) 2022 2021 Interest expense (12 ) (2 ) Contract asset interest expense (358 ) (358 ) Interest income- related party 165 - Interest income – other 10 16 Interest income 10 16 Interest expense, net $ (195 ) $ (344 ) Contract asset interest expense relates to the $ 1.7 million contract asset in connection with the $ 7.3 million start-up cost financing received from Maruho under the Cutanea acquisition share purchase agreement. The contract asset is amortized on a straight-line basis using a 6 % interest rate over the financing arrangement contract term, which ends on December 31, 2023 . Related party interest income relates to the recorded receivable of $ 6.1 million from Biofrontera AG for its 50 % share of the balance of a legal settlement.

Other Income, net

Other Income, net	12 Months Ended
	Dec. 31, 2022
Other Income and Expenses [Abstract]
Other Income, net	22. Other Income, net Other income, net consists of the following: Schedule of Other Income, Net For years ended December 31, (in thousands) 2022 2021 Reimbursed SPA costs $ - $ 539 Other, net 33 150 Other income, net $ 33 $ 689 Other, net, primarily includes gain (loss) on foreign currency transactions and gain on termination of operating leases.

Net Earnings (Loss) per Share

Net Earnings (Loss) per Share	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Income (loss) per common share:
Net Earnings (Loss) per Share	17. Net Earnings (Loss) per Share Basic net earnings per common share are calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net earnings per common share are calculated by dividing net income by the diluted weighted average number of common shares outstanding during the period. The diluted shares include the dilutive effect of stock-based awards based on the treasury stock method. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be anti-dilutive. The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data): Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 Net income (loss) $ (9,837 ) $ (850 ) $ (17,315 ) $ 4,711 Shares: Basic weighted average common shares outstanding 1,360,739 941,175 1,359,894 898,444 Add: Effect of dilutive securities Stock options and restricted stock units - - - 3,765 Diluted weighted average common shares outstanding 1,360,739 941,175 1,359,894 902,209 Net earnings (loss) per share: Basic $ (7.23 ) $ (0.90 ) $ (12.73 ) $ 5.24 Diluted $ (7.23 ) $ (0.90 ) $ (12.73 ) $ 5.22 The following table sets forth the weighted average of securities that were anti-dilutive for diluted EPS for the periods presented but which could potentially dilute EPS in the future: Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share June 30, 2023 2022 Common stock warrants 1,877,630 1,806,202 Common stock options and RSUs 106,034 42,428 Unit Purchase Options 20,182 20,182 Anti-dilutive securities excluded from computation of earnings per share 20,182 20,182 Common stock warrants include Purchase Warrants, Inducement Warrants and warrants issued in the Initial Public Offering.	23. Net Loss per Share Net Earnings (Loss) per Share Basic and diluted net loss per share attributable to common stockholders is calculated as follows (in thousands, except share and per share amounts): Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders For years ended December 31, 2022 2021 Net loss $ (640 ) $ (37,713 ) Weighted average common shares outstanding, basic and diluted 1,056,988 440,412 Net loss per share, basic and diluted $ (0.61 ) $ (85.63 ) The following table sets forth securities that were anti-dilutive for diluted EPS for the periods presented but which could potentially dilute EPS in the future: Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share December 31, 2022 2021 Common stock warrants 459,856 217,477 Common stock options and RSUs 104,127 39,241 Unit Purchase Options 20,182 20,182 Anti-dilutive securities excluded from computation of earnings per share 403,628 403,628

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	18. Commitments and Contingencies Leases The Company leases its corporate headquarters under an operating lease that expires in August 2025. The Company has the option to extend the term of the lease for one five (5) year period upon written notice to the landlord. The extension period has not been included in the determination of the ROU asset or the lease liability as the Company concluded that it is not reasonably certain that it would exercise this option. The Company provided the landlord with a security deposit in the amount of $ 0.1 million, which was recorded as other assets in the consolidated balance sheets. The Company has also entered into a master lease agreement for its vehicles. After an initial non-cancelable twelve-month period, each vehicle is leased on a month-to-month basis. Based on historical retention experience of approximately three years, the vehicles have varying expiration dates through September 2025. The components of lease expense for the three and six months ended June 30, 2023 were as follows (in thousands except lease term and discount rate): Schedule of Components of Lease Expense and Other Information Lease expense Operating Leases Amortization of ROU assets (operating lease cost) $ 265 Interest on lease liabilities 37 Total lease expense $ 302 Other Information Operational cash flow used for operating leases $ 293 Weighted -average remaining lease term (in years) 2.08 Weighted -average discount rate 6.31 % Future lease payments under non-cancelable leases as of June 30, 2023 were as follows (in thousands): Schedule of Future Commitments and Sublease Income Years ending December 31, Future lease commitments 2023 $ 270 2024 541 2025 350 Total future minimum lease payments 1,161 Less imputed interest (72 ) Total lease liability $ 1,089 Schedule of Operating Lease Liability Reported as: Operating lease liability, current $ 489 Operating lease liability, non-current 600 Total $ 1,089 Cutanea payments We have a contract in which we agreed to repay to Maruho $ 3.6 million on December 31, 2022 and $ 3.7 million on December 31, 2023 in start-up cost financing paid to us in connection with the Cutanea acquisition. We have filed for arbitration against Maruho with the International Chamber of Commerce (“ICC”) regarding issues with Maruho’s contract manufacturer that were not disclosed at the time of the Share Purchase Agreement and therefore are withholding the repayment of the start-up cost financing until a decision is reached through the arbitration process. The arbitration notes that Maruho breached the agreement with Cutanea due to undisclosed manufacturing issues and seeks damages as well as a declaration that we are not obligated to repay Maruho. We are also obligated to share product profits with Maruho equally from January 1, 2020 through October 30, 2030. Refer to Note 3, Acquisition Contract Liabilities Milestone payments with Ferrer Internacional S.A. Under the Xepi LSA, we are obligated to make payments to Ferrer upon the occurrence of certain milestones. Specifically, we must pay Ferrer i) $ 2,000,000 upon the first occasion when annual net sales of Xepi ® 25,000,000 , and ii) $ 4,000,000 upon the first occasion annual net sales of Xepi ® 50,000,000 . No Xepi ® Settlement Agreement with Biofrontera AG Pursuant to the terms of that certain Settlement Agreement, dated as of April 11, 2023, among the Company, Biofrontera AG and certain current and former directors of the Company (the “Settlement Agreement”), the Company has committed, among other things, to take the following actions: ● the Company will appoint as a Class I Director a director nominated by Biofrontera AG. See Note 20. Subsequent Events – New Board Member for details regarding the new appointment. ● the Company will begin a search, pursuant to the conditions set forth in the Settlement Agreement including a strike right granted to the aforementioned director nominated by Biofrontera AG, for an additional director candidate, who is fully independent from Biofrontera AG, Deutsche Balaton Aktiengesellschaft (“DB”) and any of their respective affiliates, to be nominated for election as a Class II Director at the Company’s 2023 annual meeting of stockholders (Amended to be nominated for election in connection with the 2024 meeting); ● the Board will increase its size to seven members, including the two directors appointed and elected pursuant to the Settlement Agreement. In addition, the Settlement Agreement contains provisions to maintain Biofrontera AG’s representation on the Board of Directors as long as it holds at least 20% of the Company’s outstanding common stock and to limit further increases in the size of the Board of Directors or changes to the Company’s stockholder rights plan. Under the Settlement Agreement, Biofrontera AG also agrees, subject to certain conditions, to vote in support of the directors nominated by, and the proposals recommended by, the Board of Directors. Licensing Agreement with Optical Tools On December 2, 2022, the Company entered into the technology transfer agreement with Optical Tools LLC (“Optical Tools”), and Stephen Tobin and Paul Sowyrda (the “Agreement”). The Agreement allowed for the transfer of the assigned patents and trademarks, and upon notification by the Company to Optical Tools, the research and development of certain prototypes. The Company paid a licensing fee of $ 0.2 million which was expensed during the year ended December 31, 2022. On May 28, 2023, the Company authorized Optical Tools to design, develop, manufacture, and deliver at least two portable photodynamic therapy lamp prototypes (“PDT Device”) using the technology in the assigned patents. The PDT Device provides illumination, based on different light profiles, to the external skin surface of the human body. The Company shall reimburse Optical Tools for all reasonable out-of-pocket, material and labor costs per the agreement. As part of the Agreement, Optical Tools will be eligible to receive regulatory and sales milestone payments totaling up to $ 1.0 million, and royalties of up to 3 % of net revenue of certain products developed under this Agreement. The Company did not make any milestone or royalty payments during the three or six months ended June 30, 2023 and 2022, respectively. Legal proceedings At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of FASB ASC Topic 450, Contingencies On November 29, 2021, the Company entered into a settlement and release agreement with respect to a lawsuit filed March 23, 2018 in the United States District Court for the District of Massachusetts in which we were alleged to have infringed on certain patents and misappropriated certain trade secrets. In the settlement, the Company and Biofrontera AG together agreed to make an aggregate payment of $ 22.5 million and engage a forensic expert to destroy data at issue in the litigation to settle the claims in the litigation. While Biofrontera AG has agreed to pay fifty percent of the settlement costs, we remain jointly and severally liable to DUSA Pharmaceuticals Inc. (“DUSA”) for the full cash settlement amount, meaning that in the event Biofrontera AG does not pay all or a portion of the amount it owes under the Agreement, DUSA could compel us to pay Biofrontera AG’s share. If either we or Biofrontera AG violates the terms of the settlement agreement, we or Biofrontera AG may be liable for a greater amount. If we become liable for more than our agreed share of the aggregate settlement amount, either of these events could have a material adverse effect on our business, prospects, financial condition and/or results of operations. As of June 30, 2023, we have reflected a legal settlement liability in the amount of $ 6.1 million for the remaining payments due under the settlement, including the estimated remaining cost of the forensic expert and a related receivable from related party of $ 3.7 million for the remaining legal settlement costs to be reimbursed in accordance with the Settlement Allocation Agreement, which provided that the settlement payments, including the cost of the forensic expert, would first be made by the Company and then reimbursed by Biofrontera AG for its share. Pursuant to the Settlement Agreement, if DUSA believes Biofrontera has violated any terms of the settlement and release agreement, the parties must engage in certain alternative dispute resolution activities, including a meeting between company representatives and non-binding mediation before a court action can be initiated.	24. Commitments and Contingencies Facility Leases The Company leases its corporate headquarters under an operating lease that expires in August 2025. The Company has the option to extend the term of the lease for one five (5) year period upon written notice to the landlord. The extension period has not been included in the determination of the ROU asset or the lease liability as the Company concluded that it is not reasonably certain that it would exercise this option. The Company provided the landlord with a security deposit in the amount of $ 0.1 million, which was recorded as other assets in the consolidated balance sheets. The Company has also entered into a master lease agreement for its vehicles. After an initial non-cancelable twelve-month period each vehicle is leased on a month to month basis. Based on historical retention experience of approximately three years, the vehicles have expiration dates ranging from February 2023 through September 2025. In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not the remaining lease term. Based on a synthetic credit rating of Ba3 and a term of 3.33 to six years, the IBR was determined to be 6% for leased liabilities at inception and 8.5% for 2022 leased liabilities The components of lease expense for the year ended December 31, 2022 was as follows (in thousands except lease term and discount rate): Schedule of Components of Lease Expense and Other Information Lease expense Operating Leases Amortization of ROU assets (operating lease cost) $ 653 Interest on lease liabilities 99 Total lease expense $ 752 Other Information Operational cash flow used for operating leases $ 781 ROU assets obtained in exchange for lease liabilities 234 Weighted -average remaining lease term (in years) 2.54 Weighted -average discount rate 6.31 % Future lease payments under non-cancelable leases as of December 31, 2022 were as follows (in thousands): Schedule of Future Commitments and Sublease Income Years ending December 31, Future lease commitments 2023 565 2024 541 2025 349 Thereafter - Total future minimum lease payments $ 1,455 Less imputed interest $ (109 ) Total lease liability $ 1,346 Schedule of Operating Lease Liability Reported as: Operating lease liability, current $ 498 Operating lease liability, non-current 848 Total 1,346 Cutanea payments We have a contract in which we agreed to repay to Maruho $ 3.6 million on December 31, 2022 and $ 3.7 million on December 31, 2023 in start-up cost financing paid to us in connection with the Cutanea acquisition. We have filed for arbitration against Maruho with the International Chamber of Commerce (“ICC”) regarding issues with Maruho’s contract manufacturer that were not disclosed at the time of the Agreement and therefore are evaluating the repayment of the $ 7.3 million of start-up costs. The arbitration notes that Maruho breached the agreement with Cutanea due to the undisclosed manufacturing issues and seeks damages as well as a declaration that we are not obligated to repay Maruho. We are also obligated to share product profits with Maruho equally from January 1, 2020 through October 30, 2030. Refer to Note 3, Acquisition Contract Liabilities Milestone payments with Ferrer Internacional S.A. Under the Xepi LSA, we are obligated to make payments to Ferrer upon the occurrence of certain milestones. Specifically, we must pay Ferrer i) $ 2,000,000 upon the first occasion when annual net sales of Xepi ® 25,000,000 , and ii) $ 4,000,000 upon the first occasion annual net sales of Xepi ® 50,000,000 . No payments were made in 2022 or 2021 related to Xepi ® Contingent liability related to shares of Biofrontera AG acquired from Maruho through subscription rights Dependent on the outcome of legal proceedings between Biofrontera AG and Maruho, the Company may be liable for an additional payout of $ 0.9 million in relation to the shares of Biofrontera AG acquired from Maruho through a subscription rights agreement. In accordance with ASC 450-20-50-3, Contingencies, Note 26. Subsequent Events. Legal proceedings At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of FASB ASC Topic 450, Contingencies On November 29, 2021, the Company entered into a settlement and release agreement with respect to a lawsuit filed March 23, 2018 in the United States District Court for the District of Massachusetts in which we were alleged to have infringed on certain patents and misappropriated certain trade secrets. In the settlement, the Company and Biofrontera AG together agreed to make an aggregate payment of $ 22.5 million and engage a forensic expert to destroy data at issue in the litigation to settle the claims in the litigation. The Company will be responsible for $ 11.25 million of the aggregate settlement amount, plus interest accrued at a rate equal to the weekly average one-year constant maturity Treasury yield and agreed to pay in three annual installments beginning with December 2021. While Biofrontera AG has agreed to pay fifty percent of the settlement costs, we remain jointly and severally liable to DUSA for the full cash settlement amount, meaning that in the event Biofrontera AG does not pay all or a portion of the amount it owes under the Agreement, DUSA could compel us to pay Biofrontera AG’s share. If either we or Biofrontera AG violates the terms of the settlement agreement, we or Biofrontera AG may be liable for a greater amount. If we become liable for more than our agreed share of the aggregate settlement amount, either of these events could have a material adverse effect on our business, prospects, financial condition and/or results of operations. As of December 31, 2022, the remaining legal settlement liability accrued for was $ 6.2 million, including the estimated remaining cost of the forensic expert. See Note 8, Other Receivables, Related Party Subsequent Events

Retirement Plan

Retirement Plan	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Retirement Benefits [Abstract]
Retirement Plan	19. Retirement Plan The Company has a defined-contribution plan under Section 401(k) of Internal Revenue Code (the “401(k) Plan”). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company matches 50% of employee contributions up to a maximum of 6% of employees’ salary. Matching contribution costs paid by the Company were $ 0.1 million and negligible for the three months ended June 30, 2023 and 2022, and $ 0.2 million and $ 0.1 million for the six months ended June 30, 2023 and 2022, respectively.	25. Retirement Plan The Company has a defined-contribution plan under Section 401(k) of Internal Revenue Code (the “401(k) Plan”). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company matches 50% of employee contributions up to a maximum of 6% of employees’ salary . For each of the years ended December 31, 2022 and 2021, matching contribution costs paid by the Company were $ 0.2 million.

Subsequent Events

Subsequent Events	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	20. Subsequent Events We have completed an evaluation of subsequent events after the balance sheet date of June 30, 2023 through the date this Quarterly Report on Form 10-Q was submitted to the SEC. Reverse Stock Split On June 28, 2023, the Company, filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to (i) effect the Reverse Stock Split of the Company’s Common Stock, and (ii) effect a related proportional reduction in the number of the Company’s authorized shares of Common Stock from 300,000,000 to 15,000,000 (the “Authorized Share Reduction”). Pursuant to the Amendment, the Reverse Stock Split and Authorized Share Reduction was effective at 11:59 p.m. on July 3, 2023 (the “Split Effective Time”), and the Common Stock began trading on the Nasdaq Capital Market on a post-split basis on July 5, 2023. The par value and other terms of the Common Stock were not affected. Following the Split Effective Time, every 20 shares of Biofrontera Inc. common stock issued and outstanding were automatically combined and reclassified into one share of common stock. Outstanding equity-based awards, warrants and other equity rights were proportionately adjusted pursuant to their terms and the number of shares authorized and reserved for issuance upon vesting of restricted stock units or exercise of stock options and warrants were reduced proportionately. No fractional shares were issued as a result of the reverse stock split. Stockholders who would otherwise hold a fractional share as a result of the Reverse Stock Split received an additional share of common stock. Under the terms of the applicable warrant agreement, the number of shares of Common Stock issuable on exercise of each warrant will be proportionately decreased. Specifically, following effectiveness of the Reverse Stock Split, every 20 shares of Common Stock that may be purchased pursuant to the exercise of public warrants now represents one share of Common Stock that may be purchased pursuant to such warrants. Accordingly, for the Company’s warrants trading under the symbol “BFRIW”, every 20 warrants will be exercisable for one share of Common Stock at an exercise price of $ 100.00 per share of Common Stock. The Reverse Stock Split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity (other than as a result of the rounding up of fractional shares). New Board Member On July 7, 2023, in connection with the Biofrontera AG settlement agreement, the board of directors of the Company appointed Heikki Lanckriet to the Board. Mr. Lanckriet will serve as a Class I Director to hold office for a term expiring at the annual meeting of the Company’s stockholders for fiscal year 2025. Mr. Lanckriet’s term as director began upon his appointment at the July 7, 2023 meeting. Mr. Lanckriet was appointed to the Board upon the nomination of Biofrontera AG, a significant stockholder of the Company, pursuant to a settlement agreement dated as of April 11, 2023, between the Company, each member of its Board of Directors at that time and Biofrontera AG. See Note 18, “ Commitments and Contingencies	26. Subsequent Events Loan and Security Agreement with MidCap. On May 8, 2023, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with MidCap Business Credit LLC, providing us with a revolving line of credit in the aggregate principal amount of up to $ 6.5 million, subject to a borrowing base. The Loan Agreement allows the Company to request advances thereunder and to use the proceeds of such advances for working capital purposes until the maturity date of May 8, 2026. The Loan Agreement is secured by a lien on substantially all of the assets of the Company, subject to customary exceptions. Advances under the Loan Agreement shall bear interest at the 30-Day Adjusted Term SOFR Rate, set monthly on the first day of the month based on 30-Day Term SOFR plus a spread adjustment of 15 basis points and subject to a floor of 2.25 %, plus 4.00 % calculated and charged monthly in arrears. In the event of a called event of default, a default interest rate of 3.00 % percent shall be added to the aforementioned rate. Under the terms of the Loan Agreement, amounts available for advances would be subject to a borrowing base, which is a formula based on certain eligible receivables and inventory. The Loan Agreement also includes an Unused Line Fee Rate of 0.375 % of the Credit Limit less all outstanding advances, which shall be paid on a monthly basis. Currently, our borrowing capacity is limited to our eligible receivables, pending consent from Biofrontera AG to allow Midcap to obtain title to Biofrontera Inc.’s inventory in the event of bankruptcy. Settlement Agreement. Pursuant to the terms of the Settlement Agreement, the major provisions are as follows: ● the Company and a member of its Board of Directors withdrew their challenges to the resolutions passed at the Biofrontera AG stockholder meeting on January 9, 2023 ● the Company will increase the Board of Directors from five to six members and appoint as a Class I Director a director nominated by Biofrontera AG to fill the vacancy, subject to certain restrictions as described in the Settlement Agreement; ● the Company will search for an additional director candidate, who is fully independent, to be nominated for election as a Class II Director at the Company’s 2023 annual meeting of stockholders; at which point the Company will increase the size of the Board of Directors to seven members (Amended to be nominated for election in connection with the 2024 meeting); ● the Board established a Related Party Transactions Committee to approve all contracts and transactions between the Company and Biofrontera AG, including any of its affiliates; ● the Company amended on April 26, 2023 that certain Stockholder Rights Agreement dated October 13, 2022, between the Company and Computershare Trust Company, N.A., as Rights Agent to increase the threshold of beneficial ownership before being deemed an Acquiring Person, solely with respect to Biofrontera AG, from 20% to 29.96% . ● In addition, the Settlement Agreement contains provisions to maintain Biofrontera AG’s representation on the Board of Directors as long as it holds at least 20% of the Company’s outstanding common stock and to limit further increases in the size of the Board of Directors or changes to the Company’s stockholder rights plan. Biofrontera AG also agrees, subject to certain conditions, to vote in support of the directors nominated by, and the proposals recommended by, the Board of Directors. Reverse Stock Split. (i) effect a reverse split at a ratio of not less than 1-for-5 and not greater than 1-for-25 and (ii) if and when the reverse stock split is effected, to decrease the number of authorized shares of the Company’s common stock in the same ratio as is selected for the reverse stock split. The final decision of whether to proceed with the Amendment shall be determined by our board of directors, in its discretion, at any time prior to August 23, 2023, the deadline for regaining compliance with Nasdaq Listing Rule 5550(a) (2). On June 28, 2023, the Company, filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to (i) effect the Reverse Stock Split of the Company’s Common Stock, and (ii) effect a related proportional reduction in the number of the Company’s authorized shares of Common Stock from 300,000,000 to 15,000,000 (the “Authorized Share Reduction”). Pursuant to the Amendment, the Reverse Stock Split and Authorized Share Reduction was effective at 11:59 p.m. on July 3, 2023 (the “Split Effective Time”), and the Common Stock began trading on the Nasdaq Capital Market on a post-split basis on July 5, 2023. The par value and other terms of the Common Stock were not affected. Licensing Agreement with Optical Tools On December 2, 2022, the Company entered into the technology transfer agreement with Optical Tools LLC (“Optical Tools”), and Stephen Tobin and Paul Sowyrda (the “Agreement”). The Agreement allowed for the transfer of the assigned patents and trademarks, and upon notification by the Company to Optical Tools, the research and development of certain prototypes. On May 28, 2023, the Company authorized Optical Tools to design, develop, manufacture, and deliver at least two portable photodynamic therapy lamp prototypes (“PDT Device”) using the technology in the assigned patents. The PDT Device provides illumination, based on different light profiles, to the external skin surface of the human body. The Company shall reimburse Optical Tools for all reasonable out-of-pocket, material and labor costs per the agreement. As part of the Agreement, Optical Tools will be eligible to receive regulatory and sales milestone payments totaling up to $ 1.0 million, and royalties of up to 3 % of net revenue of certain products developed under this Agreement. New Board Member On July 7, 2023, in connection with the Biofrontera AG settlement agreement disclosed above, the board of directors of the Company appointed Heikki Lanckriet to the Board. Mr. Lanckriet will serve as a Class I Director to hold office for a term expiring at the annual meeting of the Company’s stockholders for fiscal year 2025. Mr. Lanckriet’s term as director began upon his appointment at the July 7, 2023 meeting. Mr. Lanckriet was appointed to the Board upon the nomination of Biofrontera AG, a significant stockholder of the Company, pursuant to a settlement agreement dated as of April 11, 2023, between the Company, each member of its Board of Directors at that time and Biofrontera AG. Contingent liability related to shares of Biofrontera AG acquired from Maruho through subscription rights relieved in 2023. In July 2023, AG and Maruho settled the dispute from which the contingent payment obligation of Biofrontera Inc. under the subscription rights agreement could have arisen. Legal Claim On September 13, 2023, Biofrontera was served with a complaint filed in United Stated District Court for the District of Massachusetts by DUSA Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries LTD (collectively “DUSA” or “Plaintiffs”) in which DUSA alleges breach of contract, violation of the Lanham Act, and unfair trade practices. All claims stem from allegations that Biofrontera has promoted its Ameluz product in a manner that is inconsistent with its approved FDA labeling. Though this complaint was originally filed in the U.S. District Court for the District of Massachusetts, this matter has been transferred by agreement of the parties to the U.S. District Court for the District of New Jersey. The Company denies the Plaintiffs’ claims and intends to defend these matters vigorously. Based on the Company’s assessment of the facts underlying the above claims, the uncertainty of litigation and the preliminary stage of the case, the Company cannot estimate the possibility of a material loss, nor the potential range of loss that may result from this action. If the final resolution of the matter is adverse to the Company, it could have a material impact on the Company’s financial position, results of operations, or cash flows.

Line of Credit

Line of Credit	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Line of Credit	12. Line of Credit On May 8, 2023, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with MidCap Business Credit LLC, providing us with a revolving line of credit in the aggregate principal amount of up to $ 6.5 million, subject to a borrowing base and an availability block, with a maturity date of May 8, 2026. The Loan Agreement is secured by a lien on substantially all of the assets of the Company, subject to customary exceptions. Advances under the Loan Agreement bear interest at the 30-Day Adjusted Term Secured Overnight Financing Rate (“SOFR Rate”), set monthly on the first day of the month based on 30-Day Term SOFR plus a spread adjustment of 15 basis points and subject to a floor of 2.25%, plus 4.00% calculated and charged monthly in arrears. In the event of a called event of default, a default interest rate of 3.00% percent shall be added to the aforementioned rate. Under the terms of the Loan Agreement, amounts available for advances would be subject to a borrowing base, which is a formula based on certain eligible receivables and inventory, and a block on such availability in the amount of $ 650,000 . Currently, our borrowing capacity is limited to our eligible receivables, pending consent from Biofrontera AG to allow Midcap to obtain title to Biofrontera Inc.’s inventory in the event of bankruptcy. The borrowing base is up to 85% of accounts receivable, plus the least of (a) $ 3.3 million, (b) 50% of inventory, and (c) 85% of accounts receivable, less borrowing base reserve, if any, as defined in the Loan Agreement. The Loan Agreement also includes an Unused Line Fee Rate of 0.375 % of the Credit Limit less all outstanding advances, which shall be paid on a monthly basis. The interest rate as of June 30, 2023 was 5.31 % and interest expense for the six months ended June 30, 2023 was negligible. The Company recorded approximately $ 0.2 million of costs related to the line of credit as an asset to be amortized on a straight-line basis over the term of the line of credit. The Company recognized minimal amortization expense in connection with this Line of Credit for the six months ended June 30, 2023, which is recorded as interest expense on the accompanying consolidated statement of operations.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Basis for Preparation of the Financial Statements	Basis for Preparation of the Financial Statements The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the Company’s opinion, the unaudited condensed consolidated financial statements include all material adjustments, all of which are of a normal and recurring nature, necessary to present fairly the Company’s financial position as of June 30, 2023, the Company’s operating results for the three and six months ended June 30, 2023 and 2022, and the Company’s cash flows for the six months ended June 30, 2023 and 2022. The accompanying financial information as of December 31, 2022 is derived from audited financial statements. Interim results are not necessarily indicative of results for a full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 13, 2023. All amounts shown in these financial statements and tables are in thousands and amounts in the notes are in millions, except percentages and per share and share amounts. The Company’s significant accounting policies are discussed in Note 2—Summary of Significant Accounting Policies	Basis for Preparation of the Consolidated Financial Statements The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). These consolidated financial statements include the accounts of our wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The information presented reflects the application of significant accounting policies described below. All amounts shown in these financial statements and tables are in thousands and amounts in the notes are in millions, except percentages and per share and share amounts.
Segment Reporting		Segment Reporting Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s operating results. We operate in a single reporting segment, the commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases within the U.S. All business operations focus on the products Ameluz ® ® ®
Reverse Stock Split	Reverse Stock Split On July 3, 2023 Biofrontera Inc. effected a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $ 0.001 par value (the “Common Stock”). The Common Stock began trading on the Nasdaq Capital Market on a post-split basis on July 5, 2023. All information included in these consolidated financial statements has been adjusted, on a retrospective basis, to reflect the Reverse Stock Split as if it had been effective from the beginning of the earliest period presented, unless otherwise stated. All outstanding securities entitling their holders to purchase shares of Common Stock or acquire shares of Common Stock, including stock options, restricted stock units, and warrants, were adjusted as a result of the Reverse Stock Split, as required by the terms of those securities.	Reverse Stock Split On July 3, 2023 Biofrontera Inc. effected a 1-for-20 0.001 All information included in these consolidated financial statements has been adjusted, on a retrospective basis, to reflect the Reverse Stock Split as if it had been effective from the beginning of the earliest period presented, unless otherwise stated. All outstanding securities entitling their holders to purchase shares of Common Stock or acquire shares of Common Stock, including stock options, restricted stock units, and warrants, were adjusted as a result of the Reverse Stock Split, as required by the terms of those securities.
Use of Estimates	Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions by management that affect the reported amounts of assets and liabilities, as well as disclosure of contingent assets and liabilities, as reported on the balance sheet date, and the reported amounts of revenues and expenses arising during the reporting period. The main areas in which assumptions, estimates and the exercising of judgment are appropriate relate to, valuation allowances for receivables and inventory, valuation of contingent consideration and warrant liabilities, realization of intangible and other long-lived assets, product sales allowances and reserves, share-based payments and income taxes including deferred tax assets and liabilities. Estimates are based on historical experience and other assumptions that are considered appropriate in the circumstances. They are continuously reviewed but may vary from the actual values.	Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions by management that affect the reported amounts of assets and liabilities, as well as disclosure of contingent assets and liabilities, as reported on the balance sheet date, and the reported amounts of revenues and expenses arising during the reporting period. The main areas in which assumptions, estimates and the exercising of judgment are appropriate relate to valuation allowances for receivables and inventory, valuation of contingent consideration and warrant liabilities, realization of intangible and other long-lived assets, product sales allowances and reserves, share-based payments and income taxes including deferred tax assets and liabilities. Estimates are based on historical experience and other assumptions that are considered appropriate in the circumstances. They are continuously reviewed but may vary from the actual values.
Cash and Cash Equivalents		Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents. The Company maintains its cash balances at financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”). The FDIC provides coverage of up to $ 250,000 per depositor, per financial institution. At December 31, 2022, approximately $ 16.8 million of the Company’s cash balances were in excess of FDIC limits. The Company has not experienced any losses on these accounts and management does not believe that the Company is exposed to any significant risks.
Restricted Cash		Restricted Cash Restricted cash consists primarily of deposits of cash collateral held in accordance with the terms of our corporate credit cards, in addition to one deposit held for a sublease (see Note 13. Statement of Cash Flows Reconciliation)
Investment, Related Party		Investment, Related Party The Company accounts for its investment, related party in accordance with ASC 321, Investments — Equity Securities
Accounts Receivable		Accounts Receivable Accounts receivables are reported at their net realizable value. Any value adjustments are booked directly against the relevant receivable. We have standard payment terms that generally require payment within approximately 30 to 90 days. Management performs ongoing credit evaluations of its customers. An allowance for potentially uncollectible accounts is provided based on history, economic conditions, and composition of the accounts receivable aging. In some cases, the Company makes allowances for specific customers based on these and other factors. Provisions for the allowance for doubtful accounts are recorded in selling, general and administrative expenses in the accompanying statements of operations.
Concentration of Credit Risk and Off-Balance Sheet Risk		Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, accounts receivable and other receivables, related party. The Company maintains all of its cash and cash equivalents at a single accredited financial institution, in amounts that exceed federally insured limits. The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers using our products. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. Other receivables, related party consists of a receivable due from Biofrontera AG for its 50% share of a legal settlement and related costs for which they are jointly and severally liable for the total settlement amount. The Company has a contractual right to repayment of its share of the settlement payment from Biofrontera AG under the Settlement Allocation Agreement entered into on December 9, 2021, which provided that the settlement payments would first be made by the Company and then reimbursed by Biofrontera AG for its share. Although this receivable has credit risk, it is mitigated by the Settlement Allocation Agreement as amended on March 31, 2022, which provides certain remedies to the Company, if Biofrontera AG fails to make timely reimbursements, which the Company may implement in its sole discretion, including the ability to charge interest at a rate of 6.0% per annum for each day that any reimbursement is past due and the ability to offset any overdue reimbursement amounts against payments owed to Biofrontera AG by the Company (including amounts owed under the Company’s license and supply agreement for Ameluz ® We are dependent on two suppliers, Biofrontera Pharma GmbH and Ferrer Internacional S.A., to supply drug products, including all underlying components, for our commercial efforts. These efforts could be adversely affected by a significant interruption in the supply of our finished products.
Inventories		Inventories Finished goods consist of pharmaceutical products purchased for resale and are stated at the lower of cost or net realizable value. Cost is calculated by applying the first-in-first-out method (FIFO). Inventory costs include the purchase price of finished goods and freight-in costs. The Company regularly reviews inventory quantities on hand and writes down to its net realizable value any inventory that it believes to be impaired. Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. Once inventory is written down and a new cost basis is established, it is not written back up if demand increases.
Property and Equipment		Property and Equipment Property and equipment are recorded at cost less accumulated depreciation. Depreciation is generally applied straight-line over the estimated useful life of assets. Leasehold improvements are amortized over the shorter of the asset’s estimated useful life or the lease term. The estimated useful lives of property and equipment are: Schedule of Estimated Useful Lives of Property, Plant and Equipment Estimated Useful Life in Years Computer equipment 3 Computer software 3 Furniture and fixtures 3 5 Leasehold improvements Shorter of estimated useful lives or the term of the lease Machinery & equipment 3 4 The cost and accumulated depreciation of assets retired or sold are removed from the respective asset category, and any gain or loss is recognized in our statements of operations.
Intangible Assets		Intangible Assets Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized.
Leases		Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases (Topic 842), to enhance the transparency and comparability of financial reporting related to leasing arrangements. The Company adopted the standard effective January 1, 2022. Using the optional transition method, prior period financial statements have not been recast to reflect the new lease standard. The adoption of the new lease standard resulted in the addition of an operating lease right-of-use asset and an operating lease liability in the amount of $ 1.8 million to the consolidated balance sheet as of January 1, 2022. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate (“IBR”), which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Given the absence of an outstanding debt agreement, a synthetic credit rating analysis was used in estimating the Company’s IBR. Based on a synthetic credit rating of Ba3 and a term of 3.33 to six years, the IBR was determined to be 6% for lease liabilities at inception and 8.5% for 2022 lease liabilities . No adjustments to the right-of-use asset were required for items such as initial direct costs paid or incentives received. The Company has elected to adopt the practical expedient provided in ASC 842 and not reassess leases that existed prior to the commencement date, 1). Whether any expired or existing contracts are or contain leases, 2). Lease classification, or 3). Initial indirect costs for any existing leases. The Company has elected to combine lease and non-lease components as a single component for certain asset classes, when applicable. Operating leases are recognized on the balance sheet as operating lease right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.
Impairment of Long-Lived Assets		Impairment of Long-Lived Assets The Company considers whether events or changes in facts and circumstances, both internally and externally, may indicate that an impairment of long-lived assets held for use, including right-of-use assets, are present. To the extent indicators or impairment exist, the determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset, the assets are written down to their estimated fair values and the loss is recognized in the statements of operations. Refer to Note 12. Intangible Asset, Net.
Contingent Consideration		Contingent Consideration Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. For contingent consideration, management is responsible for determining the appropriate valuation model and estimated fair value, and in doing so, considers a number of factors, including information provided by an outside valuation advisor. Contingent consideration liabilities are reported at their estimated fair values based on probability-adjusted present values of the consideration expected to be paid, using significant inputs and estimates. Key assumptions used in these estimates include probability assessments with respect to the likelihood of achieving certain milestones and discount rates consistent with the level of risk of achievement. The fair value of contingent consideration liabilities are remeasured each reporting period, with changes in the fair value included in current operations. The remeasured liability amount could be significantly different from the amount at the acquisition date, resulting in material charges or credits in future reporting periods.
Contingencies		Contingencies Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable, and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management’s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure. Significant judgment is required in both the determination of probability and as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. Legal costs associated with legal proceedings are expensed when incurred.
Derivative Instruments		Derivative Instruments The Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in FASB Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and Derivatives and Hedging (“ASC 815”). Warrants classified as equity are recorded at fair value as of the date of issuance on the Company’s consolidated balance sheets and no further adjustments to their valuation are made. Warrants classified as derivative liabilities that require separate accounting as liabilities are recorded on the Company’s consolidated balance sheets at their fair value on the date of issuance and are revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using the Black-Scholes-Merton (“BSM”) model and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for future financings, expected volatility, expected life, yield, and risk-free interest rate. At their issuance date in October 2021, the IPO Warrants (see Note 19. Stockholders’ Equity) were accounted for as equity as these instruments met all of the requirements for equity classification under ASC 815-40. The Purchase Warrants issued in connection with the private placement offerings completed on December 1 , Note 4. Fair Value Measurements.
Fair Value Measurements		Fair Value Measurements The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC 820, Fair Value Measurements and Disclosures Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 – Unobservable inputs using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
Fair Value of Financial Instruments		Fair Value of Financial Instruments The carrying amounts reflected in the consolidated balance sheets for cash and cash equivalents, accounts receivable, other receivables, accounts payable and start-up cost financing included in acquisition contract liabilities approximate their fair values, due to their short-term nature.
Revenue Recognition		Revenue Recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers To determine revenue recognition, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when collectability of the consideration to which we are entitled in exchange for the goods or services we transfer to the customer is determined to be probable. The Company realizes its revenue primarily through the sales of its Ameluz ® Xepi ® The payment terms for sales of our pharmaceutical products are generally short-term payment terms with the possibility of volume-based discounts, co-pay assistance discounts, or other rebates. BF RhodoLED ® Variable Consideration Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which sales reserves are established and which result from discounts, rebates and other incentives that are offered within contracts between the Company and its customers. Components of variable consideration include trade discounts and allowances, product returns, government rebates, and other incentives such as patient co-pay assistance. Variable consideration is recorded on the balance sheet as either a reduction of accounts receivable, if expected to be claimed by a customer, or as a current liability, if expected to be payable to a third party other than a customer. Where appropriate, these estimates take into consideration relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. These reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, and record any necessary adjustments in the period such variances become known. Trade Discounts and Allowances Government and Payor Rebates Other Incentives ® Royalties For arrangements that include sales-based royalties, the Company recognizes royalty expense at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Royalty expense is recognized as cost of revenues. Product Warranty The Company generally provides a 36-month warranty for sales of BF-RhodoLED ® ® Contract Costs Incremental costs of obtaining a contract with a customer may be recorded as an asset if the costs are expected to be recovered. As a practical expedient, we recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. Sales commissions earned by the Company’s sales force are considered incremental costs of obtaining a contract. To date, we have expensed sales commissions as these costs are generally attributed to periods shorter than one year. Sales commissions are included in selling, general and administrative expenses.
Cost of Revenues		Cost of Revenues Cost of revenues is comprised of purchase costs of our products, third party logistics and distribution costs including packaging, freight, transportation, shipping and handling costs, and inventory adjustment due to expiring products, as well as sales-based royalties. Logistics and distribution costs totaled $ 0.5 million and $ 0.4 million for the years ended December 31, 2022 and 2021, respectively.
Share-Based Compensation		Share-Based Compensation The Company measures and recognizes share-based compensation expense for equity awards based on fair value at the grant date. The Company uses the Black-Scholes-Merton (“BSM”) option pricing model to calculate fair value of its stock option grants. The compensation cost for restricted stock awards is based on the closing price of the Company’s common stock on the date of grant. Share-based compensation expense recognized in the statements of operations is based on the period the services are performed and recognized as compensation expense on a straight-line basis over the requisite service period. The Company accounts for forfeitures as they occur. The BSM option pricing model requires the input of subjective assumptions, including the risk-free interest rate, the expected volatility of the value of the Company’s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management’s judgment. If factors change and different assumptions are used, the share-based compensation expense could be materially different in the future. These assumptions are estimated as follows: Risk-Free Interest Rate. The risk-free rate is based on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term. Expected Volatility. The Company based the volatility assumption on a weighted average of the peer group re-levered equity volatility with 80 % weight and the warrant implied volatility with 20 % weight. The peer group was developed based on companies in the biotechnology industry whose shares are publicly traded. Due to our limited historical data and the long-term nature of the awards, the peer group volatility was more heavily weighted. Expected Term. The expected term represents the period of time that options are expected to be outstanding. Due to the lack of historical exercise data and given the plain vanilla nature of the options granted by the Company, the expected term is determined using the “simplified” method, as prescribed in SEC Staff Accounting Bulletin (“SAB”) No. 107 (“SAB 107”), whereby the expected life equals the average of the vesting term and the original contractual term. Dividend Yield. The dividend yield is 0 % as the Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, a dividend on its common stock.
Foreign Currency Transactions		Foreign Currency Transactions Transactions realized in currencies other than USD are reported using the exchange rate on the date of the transaction.
Selling, General and Administrative Expense		Selling, General and Administrative Expense Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with our sales force, commercial support personnel, personnel in executive and other administrative functions, as well as medical affairs professionals. Other selling, general and administrative expenses include marketing, advertising, and other commercial costs to support the commercial operation of our product and professional fees for legal, consulting, and other general and administrative costs. Advertising costs are expensed as incurred. For the years ended December 31, 2022 and 2021, advertising costs totaled $ 0.1 million and $ 0.5 million, respectively.
Income Taxes		Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, Income Taxes The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.
Net Loss per Share		Net Loss per Share Basic and diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. When the effects are not anti-dilutive, diluted earnings per share is computed by dividing the Company’s net income attributable to common stockholders by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares outstanding during the period, including stock options, restricted stock units, and warrants, using the treasury stock method.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In September 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments	Recently Issued Accounting Pronouncements In September 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
Research and Development Costs	Research and Development Costs Research and development costs are expensed as incurred. Research and development costs include external costs of outside vendors engaged to conduct research and development activities, and other operational costs related to the Company’s research and development activities.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Estimated Useful Lives of Property, Plant and Equipment	Schedule of Estimated Useful Lives of Property, Plant and Equipment Estimated Useful Life in Years Computer equipment 3 Computer software 3 Furniture and fixtures 3 5 Leasehold improvements Shorter of estimated useful lives or the term of the lease Machinery & equipment 3 4

Acquisition Contract Liabilit_2

Acquisition Contract Liabilities (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Acquisition Contract Liabilities	Acquisition contract liabilities, net consist of the following: Schedule of Acquisition Contract Liabilities (in thousands)  June 30, 2023 December 31, 2022 Short-term acquisition contract liabilities: Contingent consideration $ 2,300 $ 2,400 Start-up cost financing 7,300 7,300 Contract asset (179 ) (358 ) Acquisition contract liabilities, net $ 7,121 $ 6,942 Long-term acquisition contract liabilities: Contingent consideration $ 2,300 $ 2,400 Total acquisition contract liabilities: Contingent consideration $ 2,300 $ 2,400 Start-up cost financing 7,300 7,300 Contract asset (179 ) (358 ) Total acquisition contract liabilities, net $ 9,421 $ 9,342	Acquisition contract liabilities, net consist of the following: Schedule of Acquisition Contract Liabilities (in thousands) December 31, December 31, Short-term acquisition contract liabilities: Start-up cost financing 7,300 3,600 Contract asset (358 ) (358 ) Acquisition contract liabilities, net $ 6,942 $ 3,242 Long-term acquisition contract liabilities: Contingent consideration $ 2,400 $ 6,200 Start-up cost financing - 3,700 Contract asset - (358 ) Acquisition contract liabilities, net $ 2,400 $ 9,542 Total acquisition contract liabilities: Contingent consideration $ 2,400 $ 6,200 Start-up cost financing 7,300 7,300 Contract asset (358 ) (716 ) Total acquisition contract liabilities, net $ 9,342 $ 12,784

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value Hierarchy Valuation Inputs	The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at June 30, 2023 and December 31, 2022 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Schedule of Fair Value Hierarchy Valuation Inputs (in thousands) Level June 30, 2023 December 31, 2022 Assets: Investment, related party 1 $ 5,935 $ 10,548 Liabilities: Contingent Consideration 3 $ 2,300 $ 2,400 Warrant liability – 2022 Purchase Warrants 3 $ 668 $ 1,129 Warrant liability - 2022 Inducement Warrants 3 $ 772 $ 1,714 Warrant liability 3 $ 772 $ 1,714	The following table presents information about the Company’s assets that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Schedule of Fair Value Hierarchy Valuation Inputs (in thousands) Level December 31, 2022 December 31, 2021 Assets: Investment, related party 1 $ 10,548 $ - Liabilities: Contingent Consideration 3 $ 2,400 $ 6,200 Warrant liability – 2021 Purchase Warrants 3 $ - $ 12,854 Warrant liability – 2022 Purchase Warrants 3 $ 1,129 $ - Warrant liability - Purchase Warrants 3 $ 1,129 $ - Warrant liability – 2022 Inducement Warrants 3 $ 1,714 $ - Warrant liability 3 $ 1,714 $ -
Schedule of Fair Value of Contingent Consideration	The following table provides a roll forward of the fair value of the contingent consideration: Schedule of Fair Value of Contingent Consideration (in thousands) Balance at December 31, 2022 $ 2,400 Change in fair value of contingent consideration (100 ) Balance at June 30, 2023 $ 2,300 Balance at December 31, 2021 $ 6,200 Change in fair value of contingent consideration (1,900 ) Balance at June 30, 2022 $ 4,300	The following table provides a roll forward of the fair value of the contingent consideration: Schedule of Fair Value of Contingent Consideration (in thousands) Balance at December 31, 2020 $ 7,602 Change in fair value of contingent consideration (1,402 ) Balance at December 31, 2021 $ 6,200 Change in fair value of contingent consideration (3,800 ) Balance at December 31, 2022 $ 2,400
Schedule of Fair Value Warrant by Using Black-Scholes Pricing Model Assumptions	The fair value at June 30, 2023 was estimated using a Black-Scholes pricing model based on the following assumptions: Schedule of Fair Value Warrant by Using Black-Scholes Pricing Model Assumptions Purchase Inducement Stock price $ 10.40 $ 10.40 Expiration term (in years) 4.38 3.42 Volatility 90.0 % 85.0 % Risk-free Rate 4.20 % 4.37 % Dividend yield 0.0 % 0.0 %	The fair value at issuance was estimated using a Black-Scholes pricing model based on the following assumptions at December 1, 2021 for the 2021 Purchase Warrants, May 16, 2022 for the Purchase Warrants and July 26, 2022 for the Inducement Warrants: Schedule of Fair Value Warrant by Using Black-Scholes Pricing Model Assumptions 2021 Purchase Purchase Inducement Stock price $ 86.60 $ 52.40 $ 32.80 Expiration term (in years) 5 5.50 4.34 Volatility 60.0 % 65.0 % 70.0 % Risk-free Rate 1.15 % 2.83 % 2.84 % Dividend yield 0.0 % 0.0 % 0.0 % The fair value was estimated using Black-Scholes pricing model based on the following assumptions as of December 31, 2021: 2021 Purchase Stock price $ 150.40 Expiration term (in years) 4.92 Volatility 60.0 % Risk-free Rate 1.25 % Dividend yield 0.0 % The fair value was estimated using Black-Scholes pricing model based on the following assumptions as of December 31, 2022 (outstanding warrants were all issued during 2022): Purchase Inducement Stock price $ 18.40 $ 18.40 Expiration term (in years) 4.88 3.92 Volatility 70 % 75 % Risk-free Rate 3.96 % 4.07 % Dividend yield 0.0 % 0.0 % Dividend yield 0.0 % 0.0 %
Schedule of Changes in Fair Value Warrant Liabilities	The following table presents the changes in the warrant liabilities measured at fair value (in thousands): Schedule of Changes in Fair Value Warrant Liabilities 2023 2022 Six Months Ended June 30, 2023 2022 Fair value at beginning of period $ 2,843 $ 12,854 Issuance of new derivative liabilities - 9,274 Change in fair value of warrant liability (1,403 ) (14,082 ) Fair value at end of period $ 1,440 $ 8,046	The following table presents the changes in the warrant liabilities measured at fair value (in thousands): Schedule of Changes in Fair Value Warrant Liabilities December 31, 2022 December 31, 2021 Fair value at beginning of year $ 12,854 $ - Issuance of new warrants 13,217 12,261 Exercise of warrants (6,840 ) (12,208 ) Change in fair value of warrant liability (19,017 ) 12,801 Warrant inducement expense 2,629 - Fair value at end of year $ 2,843 12,854

Revenue (Tables)

Revenue (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Revenue Allowance and Accrual Activities	An analysis of the changes in product revenue allowances and reserves is summarized as follows: Schedule of Revenue Allowance and Accrual Activities (in thousands): Returns Co-pay assistance program Prompt pay discounts Government and payor rebates Total Balance at December 31, 2021 $ 43 $ 101 $ 48 $ 54 $ 246 Provision related to current period sales 5 380 11 129 525 Credit or payments made during the period (5 ) (300 ) (20 ) (115 ) (440 ) Balance at June 30, 2022 $ 43 $ 181 $ 39 $ 68 $ 331 Balance at December 31, 2022 $ 48 $ 9 $ 5 $ 20 $ 82 Beginning Balance $ 48 $ 9 $ 5 $ 20 $ 82 Provision related to current period sales 3 62 3 134 202 Credit or payments made during the period - (71 ) (2 ) (59 ) (132 ) Balance at June 30, 2023 $ 51 - 6 95 152 Ending Balance $ 51 - 6 95 152	An analysis of the changes in product revenue allowances and reserves is summarized as follows: Schedule of Revenue Allowance and Accrual Activities Co-pay Prompt Government assistance pay and payor (in thousands): Returns program discounts rebates Total Balance at December 31, 2020 $ 217 $ 52 $ 15 $ 43 $ 327 Provision related to current period sales 6 423 40 168 637 Credit or payments made during the period (180 ) (374 ) (7 ) (157 ) (718 ) Balance at December 31, 2021 $ 43 $ 101 $ 48 $ 54 $ 246 Provision related to current period sales 10 574 19 210 813 Credit or payments made during the period (5 ) (666 ) (62 ) (244 ) (977 ) Balance at December 31, 2022 $ 48 $ 9 $ 5 $ 20 $ 82

Investment, Related Party (Tabl

Investment, Related Party (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Investments, All Other Investments [Abstract]
Schedule of Unrealized Gains and Losses on Investments in Equity Securities	Unrealized gains and losses on investment, related party are summarized as follows: Schedule of Unrealized Gains and Losses on Investments in Equity Securities (in thousands) 2023 2022 2023 2022 Three months ended Six months ended (in thousands) 2023 2022 2023 2022 Net losses recognized during the period on equity securities $ (1,482 ) $ - $ (4,424 ) $ - Less: Net losses recognized during the period on equity securities sold 75 - 75 - Unrealized losses recognized during the reporting period on equity securities still held at the reporting date $ (1,407 ) $ - $ (4,349 ) $ -	Unrealized gains and losses on investment, related party are summarized as follows: Schedule of Unrealized Gains and Losses on Investments in Equity Securities (in thousands) 2023 2022 2023 2022 Three months ended Six months ended (in thousands) 2023 2022 2023 2022 Net losses recognized during the period on equity securities $ (1,482 ) $ - $ (4,424 ) $ - Less: Net losses recognized during the period on equity securities sold 75 - 75 - Unrealized losses recognized during the reporting period on equity securities still held at the reporting date $ (1,407 ) $ - $ (4,349 ) $ -

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Prepaid Expenses And Other Current Assets
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets (in thousands) December 31, December 31, Receivable for common stock warrants proceeds $ - $ 3,258 Prepaid expenses 439 $ 824 Security deposits 85 149 Other 286 756 Total $ 810 $ 4,987

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consists of the following: Schedule of Property and Equipment (in thousands) December 31, December 31, Computer equipment $ 89 $ 85 Computer software 27 27 Furniture & fixtures 81 81 Leasehold improvement 368 368 Machinery & equipment 146 112 Property and equipment, gross 711 673 Less: Accumulated depreciation (507 ) (406 ) Property and equipment, net $ 204 $ 267

Intangible Asset, Net (Tables)

Intangible Asset, Net (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Asset Net	Intangible asset, net consists of the following: Schedule of Intangible Asset Net (in thousands) June 30, 2023 December 31, 2022 Xepi® license $ 4,600 $ 4,600 Less: Accumulated amortization (1,777 ) (1,568 ) Intangible asset, net $ 2,823 $ 3,032	Intangible asset, net consists of the following: Schedule of Intangible Asset Net (in thousands) December 31, December 31, Xepi ® $ 4,600 $ 4,600 Less: Accumulated amortization (1,568 ) (1,150 ) Intangible asset, net $ 3,032 $ 3,450

Cash Balances and Statement o_2

Cash Balances and Statement of Cash Flows Reconciliation (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents, and restricted cash that sum to the total shown in the consolidated statements of cash flows: Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (in thousands) June 30, 2023 December 31, 2022 Cash and cash equivalents $ 4,453 $ 17,208 Long-term restricted cash 200 200 Total cash, cash equivalent, and restricted cash shown on the consolidated statements of cash flows $ 4,653 $ 17,408	The following table provides a reconciliation of cash, cash equivalents, and restricted cash that sum to the total shown in the statements of cash flows: Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (in thousands) December 31, December 31, Cash and cash equivalents $ 17,208 $ 24,545 Short-term restricted cash - 47 Long-term restricted cash 200 150 Total cash and cash equivalent, and restricted cash shown on the statements of cash flows $ 17,408 $ 24,742

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following: Schedule of Accrued Expenses and Other Current Liabilities (in thousands) June 30, 2023 December 31, 2022 Legal settlement (See note 18) $ 6,094 $ 6,207 Employee compensation and benefits 2,816 2,850 Professional fees 1,163 1,353 Product revenue allowances and reserves 152 82 Other 511 372 Total $ 10,736 $ 10,864	Accrued expenses and other current liabilities consist of the following: Schedule of Accrued Expenses and Other Current Liabilities (in thousands) December 31, December 31, Legal settlement (See Note 24) $ 6,207 $ 5,625 Employee compensation and benefits 2,850 2,384 Professional fees 1,353 570 Product revenue allowances and reserves 82 246 Other 372 829 Total $ 10,864 $ 9,654

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Other Liabilities Disclosure [Abstract]
Schedule of Other Long Term Liabilities	Other long-term liabilities consist of the following: Schedule of Other Long Term Liabilities (in thousands) December 31, December 31, Legal settlement – noncurrent (See Note 24) $ - $ 5,625 Other 21 24 Total $ 21 $ 5,649

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company’s effective income tax rate is as follows: Schedule of Effective Income Tax Rate Reconciliation 2022 2021 Year ended December 31, 2022 2021 Income tax computed at federal statutory tax rate 21.00 % 21.00 % State taxes (5.85 )% (0.09 )% Permanent differences – non-deductible expenses (37.93 )% (1.03 )% Change in fair value of contingent consideration 133.62 % 0.78 % Change in fair value of warrant liabilities 576.27 % (7.13 )% True-ups (7.42 )% - Change in valuation allowance (685.54 )% (13.62 )% Effective income tax rate (5.85 )% (0.09 )%
Schedule of Deferred Tax Assets and Liabilities	The principal components of the Company’s deferred tax assets and liabilities consist of the following at December 31, 2022 and 2021: Schedule of Deferred Tax Assets and Liabilities (in thousands) December 31, December 31, Deferred tax assets (liabilities): Net operating loss carryforwards $ 30,450 $ 24,307 Intangible assets 4,824 5,132 Acquisition contract liabilities (96 ) (187 ) Property and equipment 123 103 Accrued expenses and reserves 890 1,693 Stock based compensation 449 - Lease liability 361 - Other - 6 ROU asset (369 ) - Investment revaluation (469 ) - Total deferred tax assets 36,163 31,054 Less valuation allowance (36,163 ) (31,054 ) Net deferred taxes $ - $ -

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Schedule of Warrants	Warrants Schedule of Warrants Warrant - PIPE Warrant - IPO* Total Warrants Weighted Average Exercise Price Balance, December 31, 2020 - - - $ - Issued 218,214 207,000 425,214 102.57 Exercised (75,357 ) (132,380 ) (207,737 ) 100.14 Balance, December 31, 2021 142,857 74,620 217,477 99.69 Issued 463,686 - 463,686 35.77 Exercised (221,307 ) - (221,307 ) 20.92 Balance, December 31, 2022 385,236 74,620 459,856 $ 52.29 * Every 20 IPO warrants are exercisable for one share of Common Stock at an exercise price of $100.00 per share of Common Stock. For financial statement purposes, the warrant shares have been decreased by a factor of 20 to effectively reflect the 1-for-20 reverse stock split. Refer to Note 26. Subsequent Events – Reverse

Equity Incentive Plans and Sh_2

Equity Incentive Plans and Share-Based Payments (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Options Assumptions	The fair value of each option was estimated on the date of the grant using the BSM option pricing model with the following assumptions: Schedule of Stock Options Assumptions Six Months Ended June 30, 2023 2022 Expected volatility 70 95 % 55 65 % Expected term (in years) 6.0 5.24 - 6.0 Risk-free interest rate 3.5 3.9 % 1.79 2.90 % Expected dividend yield 0.0 % 0.0 %	The fair value of each option was estimated on the date of the grant using the BSM option pricing model with the following assumptions: Schedule of Stock Options Assumptions 2022 2021 Expected volatility 55 % - 70 % 55.0 % Expected term (in years) 5.24 - 6.0 6.0 Risk-free interest rate 1.34 % - 4.10 % 1.34 % Expected dividend yield 0.0 % 0.0 %
Schedule of Stock Option Activity	Options outstanding and exercisable under the employee share option plan as of June 30, 2023 and a summary of option activity during the six months then ended is presented below. Schedule of Stock Option Activity Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (1) Outstanding at December 31, 2022 86,951 $ 62.16 Granted 22,477 $ 13.98 Exercised - $ - Canceled or forfeited (20,419 ) $ 54.14 Outstanding at June 30, 2023 89,009 $ 51.84 8.65 $ 13 Exercisable at June 30, 2023 26,042 $ 64.95 7.54 $ -	Options outstanding and exercisable under the employee share option plan as of December 31, 2022 and December 2021, and a summary of option activity during the year then ended is presented below. Schedule of Stock Option Activity Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (1) Outstanding at December 31, 2020 - $ - Granted 30,942 $ 95.40 Exercised - $ - Canceled or forfeited (205 ) $ 95.40 Outstanding at December 31, 2021 30,737 $ 95.40 9.94 $ 1,691 Granted 64,572 $ 48.20 Exercised - $ - Canceled or forfeited (8,358 ) $ 76.11 Outstanding at December 31, 2022 86,951 $ 62.16 9.27 $ 1 Exercisable at December 31, 2022 11,166 $ 85.48 8.99 $ - (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2022 and December 31, 2021.
Schedule of Restricted Stock Units	Schedule of Restricted Stock Units Shares Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Weighted Average Grant Date Fair Value Outstanding at December 31, 2022 17,176 $ $ 52.2 Awarded - $ $ - Vested (8,588 ) $ $ 52.2 Canceled or forfeited (3,817 ) $ $ - Outstanding at June 30, 2023 4,771 0.88 $ 50 $ 52.2	The following table summarizes the activity for RSUs during the year ended December 31, 2022 and December 31, 2021: Schedule of Restricted Stock Units Shares Weighted Average Grant Date Fair Value Outstanding balance at December 31, 2020 - $ - Granted 8,504 95.40 Issued - - Forfeited - - Outstanding balance at December 31, 2021 8,504 $ 95.40 Awarded 17,176 52.20 Issued (8,504 ) 95.40 Forfeited - - Outstanding balance at December 31, 2022 17,176 $ 52.20

Interest Expense, net (Tables)

Interest Expense, net (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule of Interest Expense	Interest expense, net consists of the following: Schedule of Interest Expense For three months ended For six months ended (in thousands) 2023 2022 2023 2022 Interest expense $ (32 ) $ (3 ) $ (33 ) $ (7 ) Contract asset interest expense (89 ) (89 ) (179 ) (179 ) Interest income – related party 40 53 94 110 Interest income – other 2 1 4 5 Interest income 2 1 4 5 Interest expense, net $ (79 ) $ (38 ) $ (114 ) $ (71 )	Interest expense, net consists of the following: Schedule of Interest Expense For years ended December 31, (in thousands) 2022 2021 Interest expense (12 ) (2 ) Contract asset interest expense (358 ) (358 ) Interest income- related party 165 - Interest income – other 10 16 Interest income 10 16 Interest expense, net $ (195 ) $ (344 )

Other Income, net (Tables)

Other Income, net (Tables)	12 Months Ended
	Dec. 31, 2022
Other Income and Expenses [Abstract]
Schedule of Other Income, Net	Other income, net consists of the following: Schedule of Other Income, Net For years ended December 31, (in thousands) 2022 2021 Reimbursed SPA costs $ - $ 539 Other, net 33 150 Other income, net $ 33 $ 689

Net Earnings (Loss) per Share (

Net Earnings (Loss) per Share (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Income (loss) per common share:
Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data): Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 Net income (loss) $ (9,837 ) $ (850 ) $ (17,315 ) $ 4,711 Shares: Basic weighted average common shares outstanding 1,360,739 941,175 1,359,894 898,444 Add: Effect of dilutive securities Stock options and restricted stock units - - - 3,765 Diluted weighted average common shares outstanding 1,360,739 941,175 1,359,894 902,209 Net earnings (loss) per share: Basic $ (7.23 ) $ (0.90 ) $ (12.73 ) $ 5.24 Diluted $ (7.23 ) $ (0.90 ) $ (12.73 ) $ 5.22	Basic and diluted net loss per share attributable to common stockholders is calculated as follows (in thousands, except share and per share amounts): Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders For years ended December 31, 2022 2021 Net loss $ (640 ) $ (37,713 ) Weighted average common shares outstanding, basic and diluted 1,056,988 440,412 Net loss per share, basic and diluted $ (0.61 ) $ (85.63 )
Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share	The following table sets forth the weighted average of securities that were anti-dilutive for diluted EPS for the periods presented but which could potentially dilute EPS in the future: Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share June 30, 2023 2022 Common stock warrants 1,877,630 1,806,202 Common stock options and RSUs 106,034 42,428 Unit Purchase Options 20,182 20,182 Anti-dilutive securities excluded from computation of earnings per share 20,182 20,182	The following table sets forth securities that were anti-dilutive for diluted EPS for the periods presented but which could potentially dilute EPS in the future: Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share December 31, 2022 2021 Common stock warrants 459,856 217,477 Common stock options and RSUs 104,127 39,241 Unit Purchase Options 20,182 20,182 Anti-dilutive securities excluded from computation of earnings per share 403,628 403,628

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Components of Lease Expense and Other Information	The components of lease expense for the three and six months ended June 30, 2023 were as follows (in thousands except lease term and discount rate): Schedule of Components of Lease Expense and Other Information Lease expense Operating Leases Amortization of ROU assets (operating lease cost) $ 265 Interest on lease liabilities 37 Total lease expense $ 302 Other Information Operational cash flow used for operating leases $ 293 Weighted -average remaining lease term (in years) 2.08 Weighted -average discount rate 6.31 %	The components of lease expense for the year ended December 31, 2022 was as follows (in thousands except lease term and discount rate): Schedule of Components of Lease Expense and Other Information Lease expense Operating Leases Amortization of ROU assets (operating lease cost) $ 653 Interest on lease liabilities 99 Total lease expense $ 752 Other Information Operational cash flow used for operating leases $ 781 ROU assets obtained in exchange for lease liabilities 234 Weighted -average remaining lease term (in years) 2.54 Weighted -average discount rate 6.31 %
Schedule of Future Commitments and Sublease Income	Future lease payments under non-cancelable leases as of June 30, 2023 were as follows (in thousands): Schedule of Future Commitments and Sublease Income Years ending December 31, Future lease commitments 2023 $ 270 2024 541 2025 350 Total future minimum lease payments 1,161 Less imputed interest (72 ) Total lease liability $ 1,089	Future lease payments under non-cancelable leases as of December 31, 2022 were as follows (in thousands): Schedule of Future Commitments and Sublease Income Years ending December 31, Future lease commitments 2023 565 2024 541 2025 349 Thereafter - Total future minimum lease payments $ 1,455 Less imputed interest $ (109 ) Total lease liability $ 1,346
Schedule of Operating Lease Liability	Schedule of Operating Lease Liability Reported as: Operating lease liability, current $ 489 Operating lease liability, non-current 600 Total $ 1,089	Schedule of Operating Lease Liability Reported as: Operating lease liability, current $ 498 Operating lease liability, non-current 848 Total 1,346

Business Overview (Details Narr

Business Overview (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2023
Proceeds from Issuance of Private Placement				$ 9,391	$ 9,391	$ 14,995
Proceeds from Issuance of Common Stock						14,943
Cash and Cash Equivalents, at Carrying Value	$ 4,453		4,453		17,208	24,545
Cash					16,800		$ 3,100
Net Cash Provided by (Used in) Operating Activities			14,025	1,987	16,199	26,715
Retained Earnings (Accumulated Deficit)	96,834		96,834		79,519	78,879
Business Combination, Contingent Consideration, Liability	9,421		9,421		9,342	12,784
Equity Securities, FV-NI, Current	5,900		5,900		10,500
Operating Income (Loss)	8,699	$ 6,212	14,190	$ 9,322	18,581	$ 25,201
Accrued Liabilities and Other Liabilities	2,400		2,400
Maruho Co. Ltd. [Member]
Business Combination, Contingent Consideration, Liability	$ 7,300		$ 7,300		7,300
Common Stock [Member]
Proceeds from Issuance of Common Stock					$ 4,600

Schedule of Estimated Useful Li

Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)	Dec. 31, 2022
Computer Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]	Leasehold Improvements [Member]
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	4 years

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)				6 Months Ended		12 Months Ended
	Jul. 03, 2023	Jul. 03, 2023	Jan. 01, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2023	Dec. 01, 2021	Dec. 21, 2020
Product Information [Line Items]
Stockholders' Equity, Reverse Stock Split	1-for-20	1-for-20
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001		$ 0.001		$ 0.001	$ 0.001		$ 0.001	$ 0.001
Cash, FDIC Insured Amount				$ 4,200,000		$ 250,000
Cash						$ 16,800,000		$ 3,100,000
Concentration Risk, License						Other receivables, related party consists of a receivable due from Biofrontera AG for its 50% share of a legal settlement and related costs for which they are jointly and severally liable for the total settlement amount. The Company has a contractual right to repayment of its share of the settlement payment from Biofrontera AG under the Settlement Allocation Agreement entered into on December 9, 2021, which provided that the settlement payments would first be made by the Company and then reimbursed by Biofrontera AG for its share. Although this receivable has credit risk, it is mitigated by the Settlement Allocation Agreement as amended on March 31, 2022, which provides certain remedies to the Company, if Biofrontera AG fails to make timely reimbursements, which the Company may implement in its sole discretion, including the ability to charge interest at a rate of 6.0% per annum for each day that any reimbursement is past due and the ability to offset any overdue reimbursement amounts against payments owed to Biofrontera AG by the Company
Operating Lease, Liability			$ 1,800,000	$ 1,089,000		$ 1,346,000
Debt Instrument, Credit Rating			Based on a synthetic credit rating of Ba3 and a term of 3.33 to six years, the IBR was determined to be 6% for lease liabilities at inception and 8.5% for 2022 lease liabilities			Based on a synthetic credit rating of Ba3 and a term of 3.33 to six years, the IBR was determined to be 6% for leased liabilities at inception and 8.5% for 2022 leased liabilities
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate							55%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0%	0%	0%	0%
Advertising Expense						$ 100,000	$ 500,000
Re-Levered Equity [Member]
Product Information [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate						80%
Warrant [Member]
Product Information [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate						20%
Logistics and Distribution [Member]
Product Information [Line Items]
Selling Expense						$ 500,000	$ 400,000

Schedule of Acquisition Contrac

Schedule of Acquisition Contract Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Start-up cost financing	$ 7,300	$ 7,300		$ 7,300
Contract asset	(179)	(358)		(716)
Acquisition contract liabilities, net	7,121	6,942		3,242
Contingent consideration	2,300	2,400	$ 4,300	6,200	$ 7,602
Acquisition contract liabilities, net	2,300	2,400		9,542
Total acquisition contract liabilities, net	9,421	9,342		12,784
Short-Term Debt [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Start-up cost financing	7,300	7,300		3,600
Contract asset	(179)	(358)		(358)
Acquisition contract liabilities, net	7,121	6,942		3,242
Long-Term Debt [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Start-up cost financing				3,700
Contract asset				(358)
Contingent consideration	$ 2,300	2,400		6,200
Acquisition contract liabilities, net		$ 2,400		$ 9,542

Acquisition Contract Liabilit_3

Acquisition Contract Liabilities (Details Narrative) - USD ($) $ in Thousands	Mar. 25, 2019	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Asset Acquisition, Contingent Consideration, Liability		$ 2,300	$ 2,400	$ 4,300	$ 6,200	$ 7,602
Long-Term Debt [Member]
Business Acquisition [Line Items]
Asset Acquisition, Contingent Consideration, Liability		2,300	$ 2,400		$ 6,200
Monte Carlo Simulation Model [Member] | Long-Term Debt [Member]
Business Acquisition [Line Items]
Asset Acquisition, Contingent Consideration, Liability		$ 2,300
Monte Carlo Simulation Model [Member] | Measurement Input, Discount Rate [Member]
Business Acquisition [Line Items]
Derivative Liability, Measurement Input	6
Cutanea Life Sciences, Inc. [Member]
Business Acquisition [Line Items]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage	100%
[custom:NoninterestBearingStartupFinancingCost]	$ 1,700
[custom:SaleOfEquityEstimatedProfitsOfContingentConsideration]	6,500
Cutanea Life Sciences, Inc. [Member] | Share Purchase Agreement [Member]
Business Acquisition [Line Items]
[custom:StartUpFinancingCosts]	$ 7,300
Biofrontera AG [Member]
Business Acquisition [Line Items]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage	29.90%
Maruho Co, Ltd. [Member]
Business Acquisition [Line Items]
[custom:StartupCostFinancingInterestRate-0]	6%
[custom:StartupCostFinancingTerm]	57 months
[custom:StartupCostFinancingMaturityDate]	Dec. 31, 2023

Schedule of Fair Value Hierarch

Schedule of Fair Value Hierarchy Valuation Inputs (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability – 2022 Purchase Warrants	$ 1,440	$ 2,843	$ 8,046	$ 12,854
Fair Value, Inputs, Level 1 [Member] | Related Party [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment, related party	5,935	10,548
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration	2,300	2,400		6,200
Fair Value, Inputs, Level 3 [Member] | Warrant Liability - 2021 Common Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability – 2022 Purchase Warrants				12,854
Fair Value, Inputs, Level 3 [Member] | Warrant Liability - 2022 Common Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability – 2022 Purchase Warrants	668	1,129
Fair Value, Inputs, Level 3 [Member] | 2022 Inducement Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 772	$ 1,714

Schedule of Fair Value of Conti

Schedule of Fair Value of Contingent Consideration (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Beginning balance, fair value of contingent consideration			$ 2,400	$ 6,200	$ 6,200	$ 7,602
Change in fair value of contingent consideration	$ 100	$ (1,900)	(100)	(1,900)	(3,800)	(1,402)
Ending balance, fair value of contingent consideration	$ 2,300	$ 4,300	$ 2,300	$ 4,300	$ 2,400	$ 6,200

Schedule of Fair Value Warrant

Schedule of Fair Value Warrant by Using Black-Scholes Pricing Model Assumptions (Details)	Jun. 30, 2023 $ / shares	Dec. 31, 2022 $ / shares	Jul. 26, 2022 $ / shares	May 16, 2022 $ / shares	Dec. 31, 2021 $ / shares	Dec. 01, 2021 $ / shares
Measurement Input, Share Price [Member] | 2021 Purchase Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock price					$ 150.40	$ 86.60
Measurement Input, Share Price [Member] | Purchase Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock price	$ 10.40	$ 18.40		$ 52.40
Measurement Input, Share Price [Member] | Inducement Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock price	$ 10.40	$ 18.40	$ 32.80
Measurement Input, Expected Term [Member] | 2021 Purchase Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Term					4 years 11 months 1 day	5 years
Measurement Input, Expected Term [Member] | Purchase Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Term	4 years 4 months 17 days	4 years 10 months 17 days		5 years 6 months
Measurement Input, Expected Term [Member] | Inducement Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Term	3 years 5 months 1 day	3 years 11 months 1 day	4 years 4 months 2 days
Measurement Input, Option Volatility [Member] | 2021 Purchase Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input					60	60
Measurement Input, Option Volatility [Member] | Purchase Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	90	70		65
Measurement Input, Option Volatility [Member] | Inducement Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	85	75	70
Measurement Input, Risk Free Interest Rate [Member] | 2021 Purchase Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input					1.25	1.15
Measurement Input, Risk Free Interest Rate [Member] | Purchase Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	4.20	3.96		2.83
Measurement Input, Risk Free Interest Rate [Member] | Inducement Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	4.37	4.07	2.84
Measurement Input, Expected Dividend Payment [Member] | 2021 Purchase Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input					0	0
Measurement Input, Expected Dividend Payment [Member] | Purchase Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0	0		0
Measurement Input, Expected Dividend Payment [Member] | Inducement Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0	0	0

Schedule of Changes in Fair Val

Schedule of Changes in Fair Value Warrant Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair value at beginning of period			$ 2,843	$ 12,854	$ 12,854
Issuance of new derivative liabilities				9,274	13,217	12,261
Exercise of warrants					(6,840)	(12,208)
Change in fair value of warrant liability	$ (375)	$ (5,371)	(1,403)	(14,082)	(19,017)	12,801
Warrant inducement expense					2,629
Fair value at end of period	$ 1,440	$ 8,046	$ 1,440	$ 8,046	$ 2,843	$ 12,854

Fair Value Measurements (Detail

Fair Value Measurements (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Jun. 28, 2023	Jul. 26, 2022	May 16, 2022
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			$ 100	$ (1,900)	$ (100)	$ (1,900)	$ (3,800)	$ (1,402)
[custom:StockIssuedDuringPeriodSharesInvestmentInEquitySecurities]	6,280,396	6,446,946
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 100
Private Placement [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											170,950
Prefunded Warrant [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
[custom:NominalStrikePrice-0]		$ 0.001					$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 0.02
Purchase Warrants [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 55.40
Inducement Warrants [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										214,286
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 33.20

Schedule of Revenue Allowance a

Schedule of Revenue Allowance and Accrual Activities (Details) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Beginning Balance	$ 82	$ 246	$ 246	$ 327
Provision related to current period sales	202	525	813	637
Credit or payments made during the period	(132)	(440)	(977)	(718)
Ending Balance	152	331	82	246
Returns [Member]
Disaggregation of Revenue [Line Items]
Beginning Balance	48	43	43	217
Provision related to current period sales	3	5	10	6
Credit or payments made during the period		(5)	(5)	(180)
Ending Balance	51	43	48	43
Co-pay Assistance Program [Member]
Disaggregation of Revenue [Line Items]
Beginning Balance	9	101	101	52
Provision related to current period sales	62	380	574	423
Credit or payments made during the period	(71)	(300)	(666)	(374)
Ending Balance		181	9	101
Prompt Pay Discounts [Member]
Disaggregation of Revenue [Line Items]
Beginning Balance	5	48	48	15
Provision related to current period sales	3	11	19	40
Credit or payments made during the period	(2)	(20)	(62)	(7)
Ending Balance	6	39	5	48
Government and Payor Rebates [Member]
Disaggregation of Revenue [Line Items]
Beginning Balance	20	54	54	43
Provision related to current period sales	134	129	210	168
Credit or payments made during the period	(59)	(115)	(244)	(157)
Ending Balance	$ 95	$ 68	$ 20	$ 54

Schedule of Unrealized Gains an

Schedule of Unrealized Gains and Losses on Investments in Equity Securities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Investments, All Other Investments [Abstract]
Net losses recognized during the period on equity securities	$ (1,482)		$ (4,424)		$ 1,747
Less: Net losses recognized during the period on equity securities sold	75		75
Unrealized losses recognized during the reporting period on equity securities still held at the reporting date	$ (1,407)		$ (4,349)

Investment, Related Party (Deta

Investment, Related Party (Details Narrative) $ in Thousands					6 Months Ended
	Jun. 30, 2023 shares	Dec. 31, 2022 shares	Nov. 08, 2022 shares	Oct. 25, 2022 € / shares shares	Jun. 30, 2023 USD ($) shares	Jun. 30, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
[custom:StockIssuedDuringPeriodSharesInvestmentInEquitySecurities]	6,280,396	6,446,946
[custom:AdditionalNumberOfSharesPurchasedThroughExerciseOfOptions]					3,377,346
Proceeds from Sale of Equity Securities, FV-NI | $					$ 178
Private Exchange Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Share Price | € / shares				€ 1
Conversion of Stock, Shares Issued				157,042
[custom:StockIssuedDuringPeriodSharesInvestmentInEquitySecurities]		6,446,946	2,623,365
[custom:AdditionalNumberOfSharesPurchasedThroughExerciseOfOptions]		3,843,581
[custom:OutstandingSharesPercent-0]		10%

Accounts Receivable, net (Detai

Accounts Receivable, net (Details Narrative) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Credit Loss [Abstract]
Accounts Receivable, Allowance for Credit Loss, Current	$ 0.2	$ 0.1	$ 0.1

Other Receivables, Related Pa_2

Other Receivables, Related Party (Details Narrative) - USD ($) $ in Thousands			12 Months Ended
	Jun. 30, 2023	Nov. 29, 2021	Dec. 31, 2021	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts Receivable, after Allowance for Credit Loss, Current	$ 2,193		$ 3,784	$ 3,748
Legal settlements receivable percentage	50%			50%
Payments for Legal Settlements		$ 22,500
Biofrontera AG [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts Receivable, after Allowance for Credit Loss, Current				$ 3,700
Accounts Receivable, after Allowance for Credit Loss, Noncurrent				2,800
Other Receivables	$ 3,700			$ 6,100
Legal settlements receivable percentage	50%
Payments for Legal Settlements	$ 6,100
Debt Instrument, Interest Rate, Stated Percentage	6%			6%
Related Party [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts Receivable, after Allowance for Credit Loss, Noncurrent			2,813	$ 2,813
Other Receivables	$ 4,000
Service Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts Receivable, after Allowance for Credit Loss				6,500
Other Receivables				$ 6,400
Payments for Legal Settlements			11,300
Litigation Settlement, Expense			$ 2,800

Inventories (Details Narrative)

Inventories (Details Narrative) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Inventory Write-down		$ 100	$ 100	$ 33
BF-RhodoLED [Member]
[custom:ProvisionForInventories]			$ 100
Xepi [Member]
Inventory Write-down				$ 300

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Prepaid Expenses And Other Current Assets
Receivable for common stock warrants proceeds			$ 3,258
Prepaid expenses		439	824
Security deposits		85	149
Other		286	756
Total	$ 929	$ 810	$ 4,987

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$ 711	$ 673
Less: Accumulated depreciation		(507)	(406)
Property and equipment, net	$ 175	204	267
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		89	85
Computer Software, Intangible Asset [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		27	27
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		81	81
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		368	368
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$ 146	$ 112

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation	$ 44	$ 54	$ 101	$ 122

Schedule of Intangible Asset Ne

Schedule of Intangible Asset Net (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Xepi® license	$ 4,600	$ 4,600	$ 4,600
Less: Accumulated amortization	(1,777)	(1,568)	(1,150)
Intangible asset, net	$ 2,823	$ 3,032	$ 3,450

Intangible Asset, Net (Details

Intangible Asset, Net (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-Lived License Agreements, Gross		$ 4,600		$ 4,600	$ 4,600
Finite-Lived Intangible Asset, Useful Life		11 years		11 years
Amortization of Intangible Assets	$ 100	$ 209	$ 209	$ 418	$ 418

Schedule of Reconciliation of C

Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 4,453	$ 17,208	$ 24,545
Short-term restricted cash			47
Long-term restricted cash	200	200	150
Total cash, cash equivalent, and restricted cash shown on the consolidated statements of cash flows	$ 4,653	$ 17,408	$ 24,742

Schedule of Accrued Expenses an

Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Legal settlement (See note 18)	$ 6,094	$ 6,207	$ 5,625
Employee compensation and benefits	2,816	2,850	2,384
Professional fees	1,163	1,353	570
Product revenue allowances and reserves	152	82	246
Other	511	372	829
Total	$ 10,736	$ 10,864	$ 9,654

Schedule of Other Long Term Lia

Schedule of Other Long Term Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Legal settlement – noncurrent (See Note 24)			$ 5,625
Other		21	24
Total	$ 40	$ 21	$ 5,649

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income tax computed at federal statutory tax rate	21%	21%
State taxes	(5.85%)	(0.09%)
Permanent differences – non-deductible expenses	(37.93%)	(1.03%)
Change in fair value of contingent consideration	133.62%	0.78%
Change in fair value of warrant liabilities	576.27%	(7.13%)
True-ups	(7.42%)
Change in valuation allowance	(685.54%)	(13.62%)
Effective income tax rate	(5.85%)	(0.09%)

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 30,450	$ 24,307
Intangible assets	4,824	5,132
Acquisition contract liabilities	(96)	(187)
Property and equipment	123	103
Accrued expenses and reserves	890	1,693
Stock based compensation	449
Lease liability	361
Other		6
ROU asset	(369)
Investment revaluation	(469)
Total deferred tax assets	36,163	31,054
Less valuation allowance	(36,163)	(31,054)
Net deferred taxes

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Unrecognized Tax Benefits		$ 0
Operating Loss Carryforwards, Valuation Allowance	$ 5,100,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	123,400,000
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration		$ 113,800,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	$ 89,200,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)					3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022	Nov. 03, 2022	Oct. 08, 2021	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Revenues					$ 5,848,000	$ 4,457,000	$ 14,580,000	$ 14,208,000	$ 28,674,000	$ 24,100,000
Other Operating Income										500,000
Loss Contingency, Receivable		$ 6,200,000							$ 6,200,000
Legal settlements receivable percentage	50%	50%			50%		50%		50%
[custom:StockIssuedDuringPeriodSharesInvestmentInEquitySecurities]	6,280,396	6,446,946
Equity Method Investment, Additional Information							3,377,346
Biofrontera Pharma GmbH [Member]
Related Party Transaction [Line Items]
Interest Income, Operating								100,000
Biofrontera AG [Member]
Related Party Transaction [Line Items]
Other Receivables	$ 3,700,000	$ 6,100,000			$ 3,700,000		$ 3,700,000		$ 6,100,000
Loss Contingency, Receivable	$ 3,700,000	6,400,000			$ 3,700,000		$ 3,700,000		6,400,000	11,300,000
Legal settlements receivable percentage	50%				50%		50%
Interest Income, Operating									100,000	0
License and Supply Agreement [Member] | Biofrontera Pharma GmbH [Member]
Related Party Transaction [Line Items]
Cost of Revenue					$ 10,400,000	6,200,000	$ 13,700,000	11,500,000	16,600,000	9,400,000
Accounts Payable	$ 4,700,000	1,300,000			4,700,000		4,700,000		1,300,000	300,000
License and Supply Agreement [Member] | Fifty Percent of Anticipated Net Price [Member]
Related Party Transaction [Line Items]
Revenues				$ 30,000,000
License and Supply Agreement [Member] | Forty Percent of Anticipated Net Price [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Revenues				30,000,000
License and Supply Agreement [Member] | Forty Percent of Anticipated Net Price [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Revenues				50,000,000
License and Supply Agreement [Member] | Thirty Percent of Anticipated Net Price [Member]
Related Party Transaction [Line Items]
Revenues				$ 50,000,000
Service Agreements [Member]
Related Party Transaction [Line Items]
Accounts Receivable, after Allowance for Credit Loss		6,500,000							6,500,000
Other Receivables		6,400,000							6,400,000
Service Agreements [Member] | Biofrontera AG [Member]
Related Party Transaction [Line Items]
Accounts Payable	200,000	200,000			200,000		200,000		200,000	200,000
Operating Costs and Expenses									700,000	700,000
Other Operating Income						$ 300,000	100,000	$ 400,000
Clinica Lamp Lease Agreement [Member] | Biofrontera Pharma GmbH [Member]
Related Party Transaction [Line Items]
Revenues										100,000
Accounts Receivable, after Allowance for Credit Loss	$ 500,000	100,000			$ 500,000		500,000		100,000	100,000
Cutanea Acquisition Agreement [Member] | Maruho Co, Ltd. [Member]
Related Party Transaction [Line Items]
Accounts Receivable, after Allowance for Credit Loss										$ 100,000
Other Receivables		$ 0							0
Share Purchase and Transfer Agreement [Member] | Maruho Co, Ltd. [Member]
Related Party Transaction [Line Items]
[custom:StockIssuedDuringPeriodValuesInvestmentInEquitySecurities]							$ 5,900,000		$ 10,500,000
[custom:StockIssuedDuringPeriodSharesInvestmentInEquitySecurities]							6,280,396		6,466,949
[custom:StockIssuedDuringPeriodSharesPurchase]			1,674,996
[custom:TotalNumberOfSharesPurchased]			6,466,946
[custom:StockIssuedDuringPeriodValuesPurchase]			$ 1,700,000

Restructuring costs (Details Na

Restructuring costs (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
Restructuring Costs	$ 0	$ 800,000
Other Restructuring Costs		$ 500,000

Schedule of Warrants (Details)

Schedule of Warrants (Details) - $ / shares		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Balance		217,477
Weighted Average Exercise Price Balance		$ 99.69
Warrants issued		463,686	425,214
Weighted Average Exercise Price of Warrants issued		$ 35.77	$ 102.57
Warrants exercised		(221,307)	(207,737)
Weighted Average Exercise Price of Warrants exercised		$ 20.92	$ 100.14
Balance		459,856	217,477
Weighted Average Exercise Price Balance		$ 52.29	$ 99.69
PIPE [Member]
Subsidiary, Sale of Stock [Line Items]
Balance		142,857
Warrants issued		463,686	218,214
Warrants exercised		(221,307)	(75,357)
Balance		385,236	142,857
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Balance	[1]	74,620
Warrants issued	[1]		207,000
Warrants exercised	[1]		(132,380)
Balance	[1]	74,620	74,620
[1]Every 20 IPO warrants are exercisable for one share of Common Stock at an exercise price of $100.00 per share of Common Stock. For financial statement purposes, the warrant shares have been decreased by a factor of 20 to effectively reflect the 1-for-20 reverse stock split. Refer to Note 26. Subsequent Events – Reverse

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative)

1 Months Ended

6 Months Ended

12 Months Ended

Oct. 25, 2022 € / shares shares

Jul. 26, 2022 USD ($) $ / shares shares

Dec. 31, 2021 USD ($) $ / shares shares

Dec. 02, 2021 USD ($) $ / shares shares

Nov. 02, 2021 USD ($) $ / shares shares

May 16, 2022 USD ($) $ / shares shares

Jun. 30, 2023 USD ($) $ / shares shares

Jun. 30, 2022 USD ($)

Dec. 31, 2022 USD ($) $ / shares shares

Dec. 31, 2021 USD ($) $ / shares shares

Jul. 03, 2023 $ / shares

Jun. 28, 2023 $ / shares shares

Jun. 27, 2023 shares

Oct. 13, 2022 $ / shares shares

Jul. 14, 2022 $ / shares shares

Dec. 28, 2021 $ / shares shares

Dec. 01, 2021 $ / shares

Dec. 21, 2020 $ / shares shares

Subsidiary, Sale of Stock [Line Items]

Common Stock, Shares Authorized | shares

15,000,000

15,000,000

15,000,000

15,000,000

15,000,000

300,000,000

15,000,000

Common Stock, Par or Stated Value Per Share

$ 0.001

$ 0.001

$ 0.001

$ 0.001

$ 0.001

$ 0.001

$ 0.001

Preferred Stock, Shares Authorized | shares

20,000,000

20,000,000

20,000,000

20,000,000

20,000,000

Preferred Stock, Par or Stated Value Per Share

$ 0.001

$ 0.001

$ 0.001

$ 0.001

$ 0.001

$ 0.001

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 100

Stock Issued During Period, Shares, New Issues | shares

214,286

[custom:ShareExercisePrice-0]

$ 5

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate

55%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.34%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term

6 years

6 years

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0%

0%

0%

0%

Proceeds from Issuance of Private Placement | $

$ 9,391,000

$ 9,391,000

$ 14,995,000

Common Stock, Shares, Issued | shares

855,237

1,367,628

1,334,950

855,237

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares

142,858

Proceeds from Warrant Exercises | $

$ 4,600,000

$ 4,630,000

$ 13,253,000

[custom:WarrantInducementCostExperience] | $

$ 2,629,000

Senior A Junior Participating Cumulative Preferred Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Preferred Stock, Shares Authorized | shares

5,000

Investor [Member]

Subsidiary, Sale of Stock [Line Items]

Payments of Stock Issuance Costs | $

$ 300,000

Maximum [Member]

Subsidiary, Sale of Stock [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 105

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate

95%

65%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

3.90%

2.90%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term

6 years

6 years

Minimum [Member]

Subsidiary, Sale of Stock [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

32.40

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate

70%

55%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

3.50%

1.79%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term

5 years 2 months 26 days

5 years 2 months 26 days

2022 Pre-Funded Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Warrants and Rights Outstanding, Term

5 years

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 55.40

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

78,450

Prefunded Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.02

May 2022 PIPE [Member]

Subsidiary, Sale of Stock [Line Items]

Proceeds from Issuance of Private Placement | $

$ 9,400,000

Private Exchange Agreement [Member]

Subsidiary, Sale of Stock [Line Items]

Share Price | € / shares

€ 1

Conversion of Stock, Shares Issued | shares

157,042

Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Warrants and Rights Outstanding, Term

5 years

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate

20%

Warrant [Member] | Inducement Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Shares Issued, Price Per Share

$ 33.20

Class of Warrant or Right, Date from which Warrants or Rights Exercisable

Jan. 27, 2023

[custom:WarrantExpirationDate]

Dec. 01, 2026

Common Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Stock Issued During Period, Shares, New Issues | shares

180,000

Common Stock [Member] | 2022 Pre-Funded Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Shares Issued, Price Per Share

$ 0.02

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 55

Common Stock, Shares, Issued | shares

78,450

Common Stock [Member] | Private Exchange Agreement [Member]

Subsidiary, Sale of Stock [Line Items]

Conversion of Stock, Shares Issued | shares

3,148,042

Warrant One [Member]

Subsidiary, Sale of Stock [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

4,286

IPO [Member]

Subsidiary, Sale of Stock [Line Items]

Common Stock, Par or Stated Value Per Share

$ 0.001

Sale of Stock, Number of Shares Issued in Transaction | shares

180,000

Shares Issued, Price Per Share

$ 100

Proceeds from Issuance Initial Public Offering | $

$ 18,000,000

Payments of Stock Issuance Costs | $

$ 3,100,000

$ 3,100,000

IPO [Member] | Black Scholes Option Pricing Model [Member] | UPO Warrants [Member]

Subsidiary, Sale of Stock [Line Items]

Warrants and Rights Outstanding | $

$ 21,000

IPO [Member] | Black Schole Option Pricing Model [Member] | UPO Warrants [Member]

Subsidiary, Sale of Stock [Line Items]

[custom:PerShareFairValueOfSharebasedPaymentAward-0]

$ 25.80

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate

60%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.15%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term

5 years

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0%

IPO [Member] | Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 100

Over-Allotment Option [Member] | Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.20

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

27,000

Stock Issued During Period, Shares, New Issues | shares

810

[custom:ShareExercisePrice-0]

$ 0.25

Over-Allotment Option [Member] | Unit Purchase Options [Member]

Subsidiary, Sale of Stock [Line Items]

Stock Issued During Period, Shares, New Issues | shares

5,400

[custom:ShareExercisePrice-0]

$ 125

UPO [Member] | Black Scholes Option Pricing Model [Member]

Subsidiary, Sale of Stock [Line Items]

Equity, Fair Value Disclosure | $

$ 300,000

UPO [Member] | Black Schole Option Pricing Model [Member]

Subsidiary, Sale of Stock [Line Items]

[custom:PerShareFairValueOfSharebasedPaymentAward-0]

$ 99

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate

60%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.15%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term

5 years

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0%

Private Placement [Member]

Subsidiary, Sale of Stock [Line Items]

Payments of Stock Issuance Costs | $

$ 300,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

170,950

Proceeds from Issuance of Private Placement | $

$ 15,000,000

Private Placement [Member] | 2022 Purchase Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

170,950

Private Placement [Member] | Purchase Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 105

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

142,857

Private Placement [Member] | Prefunded Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.002

$ 0.002

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

75,357

75,357

Sale of Stock, Price Per Share

$ 104.80

Private Placement [Member] | Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 131.20

$ 131.20

Private Placement [Member] | Warrant [Member]

Subsidiary, Sale of Stock [Line Items]

Warrants and Rights Outstanding, Term

5 years

5 years

Private Placement [Member] | Common Stock [Member]

Subsidiary, Sale of Stock [Line Items]

Stock Issued During Period, Shares, New Issues | shares

67,500

Private Placement [Member] | Common Stock [Member] | May 2022 PIPE [Member]

Subsidiary, Sale of Stock [Line Items]

Stock Issued During Period, Shares, New Issues | shares

92,500

PP UPO [Member] | Black Scholes Option Pricing Model [Member]

Subsidiary, Sale of Stock [Line Items]

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value | $

$ 300,000

PP UPO [Member] | Black Schole Option Pricing Model [Member]

Subsidiary, Sale of Stock [Line Items]

[custom:PerShareFairValueOfSharebasedPaymentAward-0]

$ 127.80

$ 127.80

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate

60%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.15%

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term

5 years

Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0%

PP UPO [Member] | Warrant [Member] | Black Scholes Option Pricing Model [Member]

Subsidiary, Sale of Stock [Line Items]

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value | $

100,000

PP UPO [Member] | Common Stock [Member] | Black Scholes Option Pricing Model [Member]

Subsidiary, Sale of Stock [Line Items]

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value | $

$ 200,000

Schedule of Stock Options Assum

Schedule of Stock Options Assumptions (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum			55%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum			70%
Expected Volatility				55%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term	6 years			6 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum			1.34%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum			4.10%
Risk-free interest rate				1.34%
Expected dividend yield	0%	0%	0%	0%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected Volatility	70%	55%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term		5 years 2 months 26 days	5 years 2 months 26 days
Risk-free interest rate	3.50%	1.79%
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected Volatility	95%	65%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term		6 years	6 years
Risk-free interest rate	3.90%	2.90%

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended		12 Months Ended
		Jun. 30, 2023		Dec. 31, 2022		Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Number of Shares Outstanding, Beginning Balance		86,951		30,737
Weighted Average Exercise Price, Beginning Balance		$ 62.16		$ 95.40
Number of Shares Outstanding, Granted		22,477		64,572		30,942
Weighted Average Exercise Price, Granted		$ 13.98		$ 48.20		$ 95.40
Number of Shares Outstanding, Exercised
Weighted Average Exercise Price, Exercised
Number of Shares Outstanding, Canceled or forfeited		(20,419)		(8,358)		(205)
Weighted Average Exercise Price, Canceled or forfeited		$ 54.14		$ 76.11		$ 95.40
[custom:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm]				9 years 11 months 8 days
Aggregate Intrinsic Value, Outstanding, Beginning Balance	[1]	$ 1		$ 1,691
Number of Shares Outstanding, Ending Balance		89,009		86,951		30,737
Weighted Average Exercise Price, Ending Balance		$ 51.84		$ 62.16		$ 95.40
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term		8 years 7 months 24 days		9 years 3 months 7 days
Aggregate Intrinsic Value, Outstanding, Ending Balance		$ 13	[2]	$ 1	[1]	$ 1,691	[1]
Number of Shares Execisable, Ending Balance		26,042,000		11,166
Weighted Average Exercise Price Options Exercisable, Ending Balance		$ 64.95		$ 85.48
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term		7 years 6 months 14 days		8 years 11 months 26 days
Aggregate Intrinsic Value, Exercisable, Ending Balance			[2]		[1]
[1]The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2022 and December 31, 2021.[2]The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at June 30, 2023.

Schedule of Restricted Stock Un

Schedule of Restricted Stock Units (Details) - Restricted Stock Units (RSUs) [Member] - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares outstanding, beginning balance	17,176	8,504
Number of shares weighted average grant date fair value, beginning balance	$ 52.20	$ 95.40
Number of shares outstanding, Awarded		17,176	8,504
Number of shares weighted average grant date fair value, Awarded		$ 52.20	$ 95.40
Number of shares outstanding, Vested	(8,588)	(8,504)
Number of shares weighted average grant date fair value,Vested	$ 52.2	$ 95.40
Number of Shares Outstanding, Forfeited	3,817,000
Number of shares weighted average grant date fair value, Canceled or forfeited
Number of shares outstanding, ending balance	4,771	17,176	8,504
Number of shares weighted average grant date fair value, outstanding ending balance	$ 52.2	$ 52.20	$ 95.40
Number of shares outstanding, Canceled or expired	(3,817,000)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms	10 months 17 days
Aggregate Intrinsic Value, Outstanding Ending Balance	$ 50

Equity Incentive Plans and Sh_3

Equity Incentive Plans and Share-Based Payments (Details Narrative) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 12, 2022	Dec. 11, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value							$ 29.28	$ 49.55
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount			$ 1.4		$ 1.4		$ 2.2
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition					2 years 1 month 6 days		2 years 3 months 18 days
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount			0.2		$ 0.2		$ 0.6
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition					10 months 24 days		1 year 4 months 24 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value							$ 0.8	$ 0
Selling, General and Administrative Expenses [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Payment Arrangement, Expense			0.2	$ 0.2	$ 0.4	$ 0.3		0.8
Selling, General and Administrative Expenses [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Payment Arrangement, Expense			$ 0.1	$ 0.4	$ 0.2	$ 0.8	$ 1	$ 0.1
2021 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant								137,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award								10 years for stock options issued under the 2021 Plan
Common Stock, Capital Shares Reserved for Future Issuance							154,359
2021 Omnibus Incentive Plan [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease)	129,490
2021 Omnibus Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease)	266,990
Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant			152,301		152,301			137,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award								10 years for stock options issued under the 2021 Plan.
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease)	266,990	129,490

Schedule of Interest Expense (D

Schedule of Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Interest expense	$ (32)	$ (3)	$ (33)	$ (7)	$ (12)	$ (2)
Contract asset interest expense	(89)	(89)	(179)	(179)	(358)	(358)
Interest expense, net	(79)	(38)	(114)	(71)	(195)	(344)
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest income	40	53	94	110	165
Nonrelated Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest income	$ 2	$ 1	$ 4	$ 5	$ 10	$ 16

Interest Expense, net (Details

Interest Expense, net (Details Narrative) - USD ($)	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
[custom:ContractAsset-0]	$ (179,000)	$ (358,000)	$ (716,000)
[custom:StartupCostFinancing-0]	$ 7,300,000	$ 7,300,000	$ 7,300,000
Legal settlements receivable percentage	50%	50%
Biofrontera AG [Member]
Debt Instrument, Interest Rate, Stated Percentage	6%	6%
Other Receivables	$ 3,700,000	$ 6,100,000
Legal settlements receivable percentage	50%
Cutanea Acquisition Agreement [Member] | Maruho Co, Ltd. [Member]
Debt Instrument, Interest Rate, Stated Percentage		6%
Other Receivables		$ 0
Maruho Co, Ltd. [Member] | Cutanea Acquisition Agreement [Member]
[custom:ContractAsset-0]	$ 1,700,000	1,700,000
[custom:StartupCostFinancing-0]	$ 7,300,000	$ 7,300,000
Debt Instrument, Interest Rate, Stated Percentage	6%
Long-Term Debt, Maturity Date	Dec. 31, 2023	Dec. 31, 2023
Biofrontera AG [Member]
Legal settlements receivable percentage		50%

Schedule of Other Income, Net (

Schedule of Other Income, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Other Income and Expenses [Abstract]
Reimbursed SPA costs		$ 539
Other, net	33	150
Other income, net	$ 33	$ 689

Schedule of Basic and Diluted N

Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Income (loss) per common share:
Net income (loss)	$ (9,837)	$ (850)	$ (17,315)	$ 4,711	$ (640)	$ (37,713)
Basic weighted average common shares outstanding	1,360,739	941,175	1,359,894	898,444	1,056,988	440,412
Basic	$ (7.23)	$ (0.90)	$ (12.73)	$ 5.24	$ (0.61)	$ (85.63)
Shares:
Stock options and restricted stock units				3,765
Diluted weighted average common shares outstanding	1,360,739	941,175	1,359,894	902,209	1,056,988	440,412
Net earnings (loss) per share:
Diluted	$ (7.23)	$ (0.90)	$ (12.73)	$ 5.22	$ (0.61)	$ (85.63)

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares shares in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share			403,628	403,628
Common Stock Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	1,877,630	1,806,202	459,856	217,477
Common Stock Options and Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	106,034	42,428	104,127	39,241
Unit Purchase Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	20,182	20,182	20,182	20,182

Schedule of Components of Lease

Schedule of Components of Lease Expense and Other Information (Details) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Amortization of ROU assets (operating lease cost)	$ 265		$ 653
Interest on lease liabilities	37		99
Total lease expense	302		752
Other Operating Activities, Cash Flow Statement	$ 293		781
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability			$ 234
Operating Lease, Weighted Average Remaining Lease Term	2 years 29 days		2 years 6 months 14 days
Operating Lease, Weighted Average Discount Rate, Percent	6.31%		6.31%

Schedule of Future Commitments

Schedule of Future Commitments and Sublease Income (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jan. 01, 2022
Commitments and Contingencies Disclosure [Abstract]
2024	$ 541	$ 565
2025	350	541
2025		349
Thereafter
Total future minimum lease payments	1,161	1,455
Less imputed interest	(72)	(109)
Total lease liability	1,089	$ 1,346	$ 1,800
2023	$ 270

Schedule of Operating Lease Lia

Schedule of Operating Lease Liability (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jan. 01, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Operating lease liability, current	$ 489	$ 498
Operating lease liability, non-current	600	848
Total	$ 1,089	$ 1,346	$ 1,800

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)				3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jan. 01, 2022	Nov. 29, 2021	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Product Liability Contingency [Line Items]
Lessee, Operating Lease, Option to Extend						option to extend the term of the lease for one five (5) year period		option to extend the term of the lease for one five (5) year period
Security Deposit	$ 250,000			$ 250,000		$ 250,000
Debt Instrument, Credit Rating		Based on a synthetic credit rating of Ba3 and a term of 3.33 to six years, the IBR was determined to be 6% for lease liabilities at inception and 8.5% for 2022 lease liabilities						Based on a synthetic credit rating of Ba3 and a term of 3.33 to six years, the IBR was determined to be 6% for leased liabilities at inception and 8.5% for 2022 leased liabilities
Revenues				5,848,000	$ 4,457,000	14,580,000	$ 14,208,000	$ 28,674,000	$ 24,100,000
Loss Contingency, Damages Sought, Value			$ 11,250,000
Payments for Legal Settlements			$ 22,500,000
Loss Contingency, Receivable								6,200,000
[custom:StartupCostFinancing-0]	7,300,000			7,300,000		7,300,000		7,300,000	7,300,000
Biofrontera AG [Member]
Product Liability Contingency [Line Items]
Payments for Legal Settlements	6,100,000
Loss Contingency, Receivable	3,700,000			3,700,000		3,700,000		6,400,000	11,300,000
Licensing Agreement [Member]
Product Liability Contingency [Line Items]
Cost, Direct Tax and License								200,000
Maruho Co, Ltd. [Member]
Product Liability Contingency [Line Items]
Loss Contingency, Damages Sought, Value								900,000
Maximum [Member] | Licensing Agreement [Member]
Product Liability Contingency [Line Items]
[custom:SalesMilestonePaymentsAmount-0]	$ 1,000,000			$ 1,000,000		$ 1,000,000
[custom:RevenuePerformanceObligationRelatedToRoyaltiesPercentage-0]	3%			3%		3%
Xepi LSA [Member]
Product Liability Contingency [Line Items]
Contractual Obligation	$ 2,000,000			$ 2,000,000	$ 4,000,000	$ 2,000,000	4,000,000	2,000,000	4,000,000
Xepi LSA [Member] | Maximum [Member]
Product Liability Contingency [Line Items]
Revenues						25,000,000	$ 50,000,000	25,000,000	$ 50,000,000
Maruho Co, Ltd. [Member]
Product Liability Contingency [Line Items]
Repayments of Related Party Debt								3,600,000
Maruho Co, Ltd. [Member] | December 31, 2022 [Member]
Product Liability Contingency [Line Items]
Repayments of Related Party Debt								3,600,000
Maruho Co, Ltd. [Member] | December 31, 2023 [Member]
Product Liability Contingency [Line Items]
Repayments of Related Party Debt								3,700,000
[custom:StartupCostFinancing-0]	3,700,000			3,700,000		3,700,000
Maruho Contract Manufacturer [Member]
Product Liability Contingency [Line Items]
Repayments of Related Party Debt								7,300,000
Facility Leases [Member]
Product Liability Contingency [Line Items]
Security Deposit	$ 100,000			$ 100,000		$ 100,000		$ 100,000

Retirement Plan (Details Narrat

Retirement Plan (Details Narrative) - USD ($) $ in Millions	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Retirement Benefits [Abstract]
Defined Contribution Plan, Nature and Effect of Change, Description		The Company matches 50% of employee contributions up to a maximum of 6% of employees’ salary.		The Company matches 50% of employee contributions up to a maximum of 6% of employees’ salary
Defined Contribution Plan, Cost	$ 0.1	$ 0.2	$ 0.1		$ 0.2

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)

Jul. 03, 2023

Jul. 03, 2023

May 28, 2023

May 22, 2023

May 08, 2023

Apr. 26, 2023

Jun. 30, 2023

Jun. 28, 2023

Jun. 27, 2023

Dec. 31, 2022

Dec. 31, 2021

Dec. 21, 2020

Subsequent Event [Line Items]

Stockholders' Equity, Reverse Stock Split

1-for-20

1-for-20

Common Stock, Shares Authorized

15,000,000

15,000,000

300,000,000

15,000,000

15,000,000

15,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 100

Security Deposit

$ 250,000

Cash, FDIC Insured Amount

$ 4,200,000

$ 250,000

Subsequent Event [Member]

Subsequent Event [Line Items]

Stockholders' Equity, Reverse Stock Split

(i) effect a reverse split at a ratio of not less than 1-for-5 and not greater than 1-for-25 and (ii) if and when the reverse stock split is effected, to decrease the number of authorized shares of the Company’s common stock in the same ratio as is selected for the reverse stock split. The final decision of whether to proceed with the Amendment shall be determined by our board of directors, in its discretion, at any time prior to August 23, 2023, the deadline for regaining compliance with Nasdaq Listing Rule 5550(a)

Common Stock, Shares Authorized

150,000

3,000,000

Subsequent Event [Member] | Licensing Agreement [Member]

Subsequent Event [Line Items]

Royalty Expense

$ 1,000,000

[custom:RoyaltyPercentage]

3%

Subsequent Event [Member] | Computer Share Trust Company [Member]

Subsequent Event [Line Items]

[custom:BeneficialOwnershipDescription]

beneficial ownership before being deemed an Acquiring Person, solely with respect to Biofrontera AG, from 20% to 29.96%

Subsequent Event [Member] | MidCap Business Credit LLC [Member]

Subsequent Event [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

$ 6,500,000

Derivative, Basis Spread on Variable Rate

15%

Derivative, Floor Interest Rate

2.25%

Derivative, Average Floor Interest Rate

4%

Derivative, Fixed Interest Rate

3%

Line of Credit Facility, Unused Capacity, Commitment Fee Percentage

0.375%

Line of Credit (Details Narrati

Line of Credit (Details Narrative) - USD ($)		6 Months Ended
	May 08, 2023	Jun. 30, 2023
Line of Credit Facility [Line Items]
Line of Credit Facility, Annual Principal Payment		$ 650,000
Debt Instrument, Interest Rate, Effective Percentage		5.31%
Long-Term Line of Credit		$ 200,000
Loan Agreement [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Annual Principal Payment	$ 3,300,000
Revolving Credit Facility [Member] | Loan Agreement [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 6,500,000
Debt Instrument, Interest Rate Terms	Advances under the Loan Agreement bear interest at the 30-Day Adjusted Term Secured Overnight Financing Rate (“SOFR Rate”), set monthly on the first day of the month based on 30-Day Term SOFR plus a spread adjustment of 15 basis points and subject to a floor of 2.25%, plus 4.00% calculated and charged monthly in arrears. In the event of a called event of default, a default interest rate of 3.00% percent shall be added to the aforementioned rate.
[custom:UnusedLineFeeRate]	0.375%